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Tiivistelmä 
 
Suomessa on tällä hetkellä arvioiden mukaan n. 4 000 – 5 000 opioidien väärinkäyttäjää, joista 
n. 2.400 on  lääkkeellisen  korvaushoidon piirissä.  Korvaushoito on lukuisissa tutkimuksissa 
todettu tehokkaimmaksi opioidiriippuvuuden hoitomuodoksi. Siitä huolimatta suhtautuminen 
tähän hoitoon on edelleenkin ristiriitaista, mikä on myös näkynyt Suomen 
huumausainepolitiikassa sekä hoitojärjestelmän kehittämisessä ja kehityksessä. Erityisenä 
huolena on edelleen korvaushoitolääkkeiden buprenorfiinin ja metadonin väärinkäyttö tai 
niiden päätyminen katukauppaan. Muista Pohjoismaista poiketen buprenorfiini on Suomessa 
eniten suonensisäisesti väärinkäytetty opioidi. Tämä asettaa erityisiä haasteita hoidon 
kehittämiselle. 
 
Tämän tutkimuksen tarkoituksena on tutkia sellaisten kliinisten menetelmien tai 
toimintatapojen käyttöä korvaushoidossa, jotka saattavat vähentää lääkkeiden väärinkäyttöä, 
pienentää henkilöresurssien tarvetta, parantaa potilaiden hoitoon sitoutumista ja siten kohentaa 
hoidon tuloksellisuutta. Suomessa otettiin Euroopan ensimmäisenä maana käyttöön pienemmän 
väärinkäyttöpotentiaalin, kuin pelkkää mono-buprenorfiinia sisältävä lääke, omaava 
buprenorfiini-naloksoni yhdistelmävalmiste. Ensimmäisessä osatyössä selvitettiin aiheuttaako 
siirtyminen mono-buprenorfiinista buprenorfiini-naloksoniin potilaille haittavaikutuksia ja 
vaikuttaako se potilaiden hoitoon sitoutumiseen. Toinen keino väärinkäytön vähentämiseksi on 
buprenorfiini tabletin murskaaminen annostelun yhteydessä. Aiemmin ei ollut tietoa miten 
murskaaminen vaikuttaa mono-buprenorfiinin imeytymiseen ja kliiniseen tehoon ja toisessa 
osatyössä selvitettiin miten mono-buprenorfiini lääkkeen murskaus vaikuttaa seerumitasoihin ja 
kokevatko potilaat haittavaikutuksia. Eräs merkittävä ongelma on ollut osan potilaiden huono 
sitoutuminen hoitoon, jossa yhtenä merkittävänä tekijänä on ollut päihdeseulojen antamisen 
tiukka kontrollointi. Kolmannessa osatyössä selvitettiinkin vaikuttaako virtsaseulojen 
ottaminen ilman valvontaa ja uudenlaista merkkiainetta käyttäen potilaiden 
hoitomyöntyvyyteen sekä henkilökunnan resurssien käyttöön. Poikkeuksellisen laaja 
buprenorfiinin väärinkäyttö Suomessa tarjoaa erinomaisen mahdollisuuden seurata sen 
väärinkäyttöä ja katukauppaa. Viimeisessä osastyössä selvitettiinkin mitkä ovat opioidien 
väärinkäytön ja laittoman kaupan trendit seitsemän vuoden väärinkäytön ja katukaupan 
seurantatutkimuksella. 
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Tutkimus osoitti, että uuden buprenorfiini-naloksoni yhdistelmävalmisteen käyttö on yhtä 
turvallista kuin pelkän mono-buprenorfiinin eikä pääsääntöisesti annosmuutoksia vaihdon 
yhteydessä tarvita. Lääkkeen murskaaminen ei vaikuttanut seerumitasoihin eivätkä 
tutkimushenkilöt kokeneet verrokkiryhmää enempää tai vähempää haittavaikutusta. Tämän 
perusteella arvioitiin, että tablettien murskaaminen ei vaikuta lääkkeen kliiniseen tehoon, ollen 
siten farmakologisesti yhtä tehokasta kuin kokonaisen tabletin käyttäminen. Tutkimus, jossa 
selvitettiin uuden merkkiainepohjaisen päihdeseulan hyötyjä ja haittoja, osoitti, että sekä 
potilaat että hoitohenkilökunta kokivat sen selkeästi mukavammaksi kuin perinteisen 
silmämääräisen valvontaan perustuvan päihdeseulan Tämä todennäköisesti lisää potilaiden 
hoitomyöntyvyyttä ja kiinnittymistä hoitoon. Lisäksi todettiin, että kyseinen uusi päihdeseula 
vähentää huomattavasti seulatutkimuksiin käytettävää työaikaa mikä todennäköisesti myös 
lisää hoidon tehokkuutta sekä tuloksellisuutta henkilökunnan pystyessä keskittymään enemmän 
hoitotyöhön. Seurantatutkimus osoitti, että buprenorfiini-naloksoni yhdistelmää väärinkäytettiin 
vähemmän ja yhdistelmävalmisteen ”katuhinta” oli koko seurantajakson ajan selvästi alempi 
kuin pelkän mono-buprenorfiinin, joten siten voidaan ajatella sillä olevan pienempi 
väärinkäyttöpotentiaali kuin pelkällä mono-buprenorfiini valmisteella.  
 
Tutkimukset osoittivat, että on mahdollista käyttää useita keinoja, joilla voidaan vähentää 
buprenorfiinin väärinkäyttöpotentiaalia, lisätä potilaiden hoitomyöntyvyyttä ja kiinnittymistä 
hoitoon, ja ne tulisikin ottaa laajamittaiseen kliiniseen käyttöön. 
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Abstract 
 
The purpose of this study was to investigate whether pharmacological or clinical management 
methods could improve patients' adherence to treatment and reduce the resource burden, thus 
improving treatment effectiveness. 
 
Finland was the first country in Europe to use buprenorphine-naloxone combination medication 
as part of opioid maintenance treatment (OMT), which was expected to have lower potential 
for diversion into the drug market. The study investigated whether the transition from mono-
buprenorphine to buprenorphine-naloxone combination would cause adverse events or lower 
patient compliance. One way to reduce the diversion of buprenorphine medication is to crush 
the tablet when administering it, this has not been studied earlier, and it was investigated 
whether crushing mono-buprenorphine tablets would influence the kinetics and serum levels of 
buprenorphine, or whether patients would have adverse events following the use of crushed 
tablets. One main problem in OMT has been patient compliance and adherence to treatment. 
One main component has been visually supervised urine drug screens. Thus it was investigated 
whether a new unsupervised screening method would affect urine testing reliability, patient 
compliance, and the time/resources used by personnel in screening. The large buprenorphine 
abuse problem in Finland provides good possibilities for being able to study the abuse. A 
seven-year follow-up study evaluated the trends in street buprenorphine prices, intravenous 
abuse doses, and its abuse potential in Finland. 
 
The studies showed that the use of the new buprenorphine-naloxone combination product is as 
safe as mono-buprenorphine alone, and that no dose adjustments are needed during medication 
change. Crushing of the mono-buprenorphine tablet did not affect serum levels or 
buprenorphine kinetics, and the study subjects did not experience more or less adverse events 
than the control group. It was concluded that crushing is a safe and effective management for 
patients with high risk of medication abuse or diversion. The study with the new marker-based 
urine drug screen indicated that the new method did not jeopardize the safe and reliable 
assessment of concomitant drug use. Both patients and medical staff thought it was more 
comfortable than the traditional visually controlled screen. The new method saved considerable 
time previously spent on controlling the screen. So it was concluded that the new screening 
method improves patient compliance, reduces the burden of the control time and thus may 
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increase the effectiveness of the treatment. The long-term follow-up study revealed that the 
street price of the new combination product is significantly less than of the mono-
buprenorphine product and that the price difference remained the same during the follow-up 
period. Thus it was concluded that the abuse potential of the combination product is less than 
that of mono-buprenorphine. 
 
The studies demonstrate that there are several effective methods for reducing the abuse of OMT 
medications, and that patient compliance and thus the outcomes of treatment can both be 
improved. These methods should be used broadly in the clinical management of OMT. 
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Abbreviations 
 
AIHW  Australian Institute of Health and Welfare 
A-clinic  Specialized alcohol and drug rehabilitation clinic 
ANOVA  Analysis Of Variance between groups 
ASAM  Ameriacn Spcoety of Addiction Medicine 
APA  American Psychological Association 
AUC 0–24  The Area under the Concentration-time curve over 24 hours 
BZD  Benzodiazepine 
CI  Confidence interval 
Cmax  Maximum observed serum drug concentration 
CYP 3A4  CYP3A4 cytochrome P450, superfamily of enzymes 
DDI  Drug-drug interaction 
df  degrees of freedom 
DSM-IV Diagnostic and Statistical Manual of Mental Disorders, fourth 
edition 
EMCDDA  European Monitoring Centre for Drugs and Drug Addiction 
EXCEL  spread sheet program by Microsoft 
EUROPAD  European Opiate Addiction Treatment Assosiation 
FDA  Food and Drug Administration (U.S.) 
GC-MS  Gas chromatography–mass spectrometry 
h  hour  
HCV  Hepatitis C virus 
HDL Drug Rehabilitation Centre, Helsinki Deaconess Institute,  
HIV  Human immunodeficiency virus 
HPLC  High-performance liquid chromatography 
HUS/OPRI Hospital District of Helsinki and Uusimaa, Opiate Maintenance 
Polyclinic, Department of Drug Psychiatry, Helsinki University 
Hospital 
ICD-10 International Statistical Classification of Diseases and Related 
Health Problems 10th Revision 
ICH The International Conference on Harmonisation of Technical 
Requirements for Registration of Pharmaceuticals for Human Use 
IHRA International Harm Reduction association 
i.v  intravenous 
LCMS  Liquid chromatography–mass spectrometry 
 
 
  
10 
 
 
MBDB N-methyl-1,3-benzodioxolylbutanamine, entactogen of the  
phenethylamine chemical class 
MDMA 3,4-methylenedioxy-N-methylamphetamine, empathogenic drug of  
the phenethylamine and amphetamine classes of drugs 
MDA 3,4-methylenedioxyamphetamine, entactogenic drug of the  
phenethylamine and amphetamine chemical classes 
MDEA  3,4-methylenedioxy-N-ethylamphetamine), analog of MDMA 
MedDRA  Medical Dictionary for Regulatory Activities 
MMT  Methadone maintenance treatment 
MSAH  Ministry of Social Affairs and Health 
MSTFA  N-methyl-N-trimethylsilyl-trifluoro- acetamide 
NIH  National Institutes of Health (U.S.) 
NM  New marker labelling method 
OMT  Opioid maintenance treatment 
OM  Opioid maintenance  
ORT  Opioid replacement treatment 
OST   Opioid substitution treatment 
RAAHE  Raahe Mental Health Clinic, Primary Health Care Centre 
SAMSHA  Substance Abuse and Mental Health Services Administration, USA 
SD  Standard deviation 
SOWS  Subjective Opiate Withdrawal Scale 
THC  Tetrahydrocannabinol, cannabis 
THL  National Institute for Health and Welfare 
Tmax  Time to maximum concentration of drug in serum 
TS  Traditional supervised urine sampling 
Tre-K-Klinikka Drug Rehabilitation Polyclinic at Tampere City, K-Clinic, A-clinic 
Foundation 
VAS  Visual analogue scale 
WinNonlin Pro Industry-Standard PK/PD Modelling and Analysis program 
WHO  World Health Organisation 
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1. Introduction 
 
Opioid addiction is a chronic, relapsing disorder. Left untreated, high morbidity and mortality 
rates are seen (Cruts, Buster et al. 2008; Clausen, Waal et al. 2009; Degenhardt, Randall et al. 
2009; Vicente, Giraudon et al. 2009). Psychosocially assisted pharmacological treatment of 
opiate dependence is used to reduce illicit opiate abuse, reduce the harms related to opiate 
abuse and improve quality of life. Opioid maintenance treatment (OMT) is often also referred 
to as Opioid substitution (OST) or opioid replacement (ORT) treatment. The most commonly 
used agonists are methadone, mono-buprenorphine and buprenorphine-naloxone. Of the 
various treatment options that have been examined, the opioid agonist treatment combined with 
psychosocial assistance has been found to be the most effective (McLellan, Arndt et al. 1993; 
Sees, Delucchi et al. 2000; Amato, Minozzi et al. 2004b; Amato, Minozzi et al. 2004c; Amato, 
Minozzi et al. 2008a; Amato, Minozzi et al. 2008; WHO 2009). OMT is more cost-effective 
compared to detoxification (Mattick, Breen et al. 2003; Mattick, Kimber et al. 2003; Mattick, 
Kimber et al. 2008; Minozzi, Amato et al. 2008b; Mattick, Breen et al. 2009; Polsky, Glick et 
al. 2010; Treatment of drug abuse: current care summary2012). 
 
The diversion, misuse and non-medically supervised use of methadone, mono-buprenorphine 
and buprenorphine-naloxone combination represent a complex medical and social issue 
(Larance, Degenhardt et al. 2011b). Maintenance treatment for opioid dependence often 
involves supervised daily administration of a dose of methadone or buprenorphine, which bind 
significant resources to the treatment sites and also constrains the patient’s possibilities to carry 
out normal social activities (Sullivan, Chawarski et al. 2005), which negatively affects 
rehabilitation. In Finland, buprenorphine is the most widely abused opioid, causing fatal 
poisonings (Steentoft, Teige et al. 2006; Simonsen, Normann et al. 2011). A sublingual tablet 
combining buprenorphine and naloxone has been developed to deter diversion and intravenous 
misuse, and to be more suitable to less supervised administration. Even so there have been 
doubts about whether the new formulation of the drug functions as planned, while patients have 
been reluctant to use it following concern about the possible side effects of the naloxone 
compound. The profusion of national guidelines has led to many different OMT models and 
different approaches to clinical management in different countries and even within a country. 
Thus research and guidance to improve clinical management is needed. 
  
13 
 
In Finland approximately 4000–5000 persons are opioid abusers and approximately 2400 of 
these are in opioid maintenance treatment (OMT). It has been shown in numerous studies that 
pharmacologically assisted opioid maintenance therapy is the most effective method of 
treatment. Nevertheless, this approach to treatment is still controversial, which is partly 
reflected in Finland's drug policy and in the development of the clinical management of the 
treatment systems in Finland. A particular concern in Finland has been the abuse of 
maintenance medications or their diversion into the street market. This is partly due to the 
exceptional situation in Finland, where buprenorphine is the most intravenously abused opioid. 
This has overshadowed the use of maintenance treatment and created special challenges for 
treatment and its further development. 
 
In Finland, OMT on a larger scale did not begin until the late 1990s, after which several 
decrees of the Ministry for Social Affairs and Health have guided the treatment systems and 
clinical management. The latest decree is from 2008, with an emphasis on shifting evaluations 
and treatments to primary health care as well as allowing pharmacy distribution for the 
buprenorphine-naloxone combination. The reforms are aimed at improving access to care, and 
thereby increasing the number of patients treated. Although the number of patients has risen 
steadily in Finland, it is still relatively lower than in other Nordic countries. The transference of 
maintenance treatments to primary health care and especially the use of pharmacy distribution 
have not developed as expected. Regarding the Current Care Guidelines, the implementation of 
OMT varies from one municipality to another and even from clinic to clinic. Also some of the 
current clinical practices demand resources that could be used for rehabilitation. Because the 
treatment is usually long-term, some of these procedures can decrease patient compliance and 
treatment outcomes. 
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2. Review of literature 
 
2.1 Diagnosis and assessment of opioid dependence 
 
2.1.1 Opioids 
 
The term ‘opioids’ refers to a class of psychoactive substances derived from the poppy plant 
(including opium, morphine and codeine), as well as semi-synthetic forms (including heroin) 
and synthetic compounds (including methadone and buprenorphine) and endogenous 
compounds with similar properties. The term ‘opiate’ refers strictly to the subset of opioids that 
are naturally occurring or semi-synthetic, and therefore include heroin and morphine. Opioids 
are also classified by their potency on the opioid receptor system: for example, codeine and 
tramadol are considered weak, buprenorphine is considered semi-strong, and morphine, 
heroine, methadone and fentanyl are considered strong opioids. The three major subgroups of 
opioid receptors are delta, kappa and mu, and are mainly found in the brain and spinal cord, 
though also at other locations. The subgroups have partly overlapping, different functions and 
as an example the mu receptor is central in pain relief but also induces respiratory depression 
and euphoria, which plays an important role in opioid dependency. The delta receptor in the 
brain is involved in pain relief and antidepressant effects. Kappa receptors in the brain and 
spinal cord are linked with sedation, spinal analgesia and pupil constriction. Opioids may 
produce unwanted side effects such as nausea, vomiting, dizziness, and constipation, and even 
potentially fatal respiratory depression when overdosed. Especially in the case of opioids, the 
adapted tolerance following regular use can be remarkable and addicted persons can use doses 
that would be deadly for first-time opioid users (Salaspuro M. 2003). 
 
Opioids are widely used in medicine for pain treatment due to their ability to relieve even 
severe pain related to, for example, cancer (Zeppetella and Ribeiro 2006; Wiffen and McQuay 
2007). For other medical conditions they are rarely used because of their addictive nature and 
side-effects. 
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2.1.2 Drug addiction and dependence 
 
Drug misuse is defined as the use of a substance for a purpose not consistent with legal or 
medical guidelines. Illicit use of opioids generally involves injecting or inhaling the fumes 
produced by heating the drug. Even though addiction has also long been recognized as a 
chronic relapsing brain disorder (Leshner 1997) the exact neurobiological processes behind it 
remain little understood (Buckland 2008).  
 
The genetics behind addiction and vulnerability have been intensively research, but no clear 
breakthrough have been made (Duaux, Krebs et al. 2000; Kreek, Nielsen et al. 2004). From a 
psychiatric perspective, drug addiction displays aspects of both impulse control disorders and 
compulsive disorders (APA 1994), The strongest neurobiological hypothesis behind these 
processes are that addiction is a neurological dysfunction of brain reward (Koob, Ahmed et al. 
2004; Berridge 2007; Volkow 2010; Volkow, Wang et al. 2010; Hommer, Bjork et al. 2011), 
motivation (Di Chiara 1998; Salamone, Correa et al. 2003), memory and the related circuitry 
(Koob 1998; Koob, Sanna et al. 1998; Kreek and Koob 1998; Koob and Le Moal 2001; Weiss 
and Koob 2001), as stated in the most recent definition of the American Society of Addiction 
Medicine. Even though this neurobiological aspect has been emphasised lately, there are 
several essential non-biological components of addiction, which include cultural and social 
values, situational factors, developmental variations, personality and cognitive differences. 
There has been and still is an on-going struggle between these two perspectives, even though 
clinically they cannot be separated from each other without compromising treatment outcomes. 
Physical dependence, tolerance and addiction are discrete and different phenomena that often 
make discussion challenging. The terms used in this theses will be those recommended and 
used by the American Academy of Pain Medicine, the American Pain Society, and the 
American Society of Addiction Medicine (ASAM 2001): 
 
I Addiction 
Addiction is a primary, chronic, neurobiological disease, with genetic, psychosocial, and 
environmental factors influencing its development and manifestations (ASAM 2011). It is 
characterized by behaviours that include one or more of the following: impaired control over 
drug use, compulsive use, continued use despite harm, and craving. 
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II Physical Dependence 
Physical dependence is a state of adaptation that is manifested by a drug-class-specific 
withdrawal syndrome that can be produced by abrupt cessation, rapid dose reduction, 
decreasing blood level of the drug, and/or administration of an antagonist. 
 
III Tolerance 
Tolerance is a state of adaptation in which exposure to a drug induces changes that result in a 
diminution of one or more of the drug’s effects over time. 
 
The way that drugs are experienced and how they bring about reinforcement differs greatly 
between individuals. The still unresolved question is why only a small proportion of all 
individuals that have used an abused drug will become addicted (Piazza and Le Moal 1996; 
Miller, Guttman et al. 1997; Duaux, Krebs et al. 2000; Kreek, Nielsen et al. 2004; Levran, 
Yuferov et al. 2012). Besides the neurobiological aspects mentioned above, two theories have 
addressed this issue from different angles, either social or psychiatric. The first theory proposes 
that if an individual because of environmental factors has a greater chance of using a drug, they 
will become addicted because of repeated use of it. The theory thus suggests that repeated drug 
use will bring about changes in the brain leading to addiction. The other theory proposes that if 
an individual is especially vulnerable to addiction because of their physiology this can lead to a 
pathological reaction to the drug, culminating in addiction. It is likely that both theories 
contribute to the individual variability in vulnerability to addiction, as has been shown in recent 
studies (Uhart and Wand 2009; Pani, Maremmani et al. 2010; Fenton, Keyes et al. 2012; Keyes, 
Eaton et al. 2012; Martins, Fenton et al. 2012; Read and Bentall 2012) 
 
2.1.3 Definition of opioid dependence 
 
Opioid dependence is recognized as a medical condition with cognitive, behavioural and 
physiological dimensions. Illicit use of opioids generally involves injecting, inhaling the fumes 
produced by heating the drug or sniffing opioid powder. Dependence does not develop without 
regular use, but regular use alone is not sufficient to cause dependence. It develops over time 
from initial experimental and recreational use to more intensive and compulsive use, usually 
daily. Once dependence on opioids is well established, it becomes a chronic relapsing 
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condition. Many opioid addicted individuals also show psychiatric comorbidity (Maremmani, 
Pani et al. 2010; Fenton, Keyes et al. 2012), but it is unclear whether the psychopathology was 
pre-existing or is a result of the opioid abuse (Pani, Maremmani et al. 2010; Maremmani, 
Dell'Osso et al. 2011). Opioid dependence is also related to higher mortality rates and costs to 
society, especially the criminal and justice system, than any other drugs (Cruts, Buster et al. 
2008; Gibson, Degenhardt et al. 2008; Clausen, Waal et al. 2009; Degenhardt, Randall et al. 
2009; Vicente, Giraudon et al. 2009; Hedrich, Alves et al. 2012; Nilsson I. 2012; Soyka, Trader 
et al. 2012). 
 
Opioid dependence is defined according to the International Statistical Classification of 
Diseases and Related Health Problems (ICD-10)(WHO 1995) and the Diagnostic and Statistical 
Manual of Mental Disorders (DSM-IV)(APA 1994). These classifications differ in some 
aspects and in this thesis, ICD-10 is used, as it is the officially used standard classification in 
Europe. DSM-IV is used mainly in the United States and much less often in Europe in the field 
of psychiatry, because it covers the psychiatric aspects of addiction in more detail. For this 
reason, it is also widely used in international research, while in many countries, addictions are 
treated as part of psychiatry. In many European studies the ICD-10 and DSM-IV are used side 
by side to make comparisons of different studies easier. 
 
The ICD-10 diagnostic system is used in Finland and a description of the dependency 
syndrome states: A cluster of behavioural, cognitive, and physiological phenomena that 
develop after repeated substance use and that typically include a strong desire to take the drug, 
difficulties in controlling its use, persisting in its use despite harmful consequences, a higher 
priority given to drug use than to other activities and obligations, increased tolerance, and 
sometimes a physical withdrawal state. Opioid dependence can be diagnosed if three or more of 
these traits are fulfilled continuously during a one-month period or if these periods are shorter 
repeated over a 12-month period: 
1. a strong desire or sense of compulsion to take opioids 
2. difficulties in controlling opioid use 
3. increased tolerance over time 
4. after stopping the use of opioids the patient suffers from a physiological withdrawal state  
5. the patient also progressively neglects alternative pleasures or interests because of opioid use  
6. misuse persists despite clear physical or psychiatric harm to the patient. 
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In addition using the DSM-IV criteria, used more for research purposes, one should also 
specify whether opioid dependence is physiological dependence (i.e. there is evidence of 
tolerance or withdrawal) or without physiological dependence (i.e. no evidence of tolerance or 
withdrawal). In DSM- IV the essential criteria are tolerance, specified as marked increase in the 
amount and  decrease in effect, characteristic withdrawal symptoms; leading to opioids taken to 
relieve withdrawal. Also opioids are taken in larger amounts and for longer periods than 
intended. The patient also has a persistent desire or has had repeated unsuccessful attempts to 
quit. The patient uses much time/activity to obtain, use and recover opioids. With ongoing 
abuse, important social, occupational or recreational activities are surrendered or reduced by 
the patient and the use continues despite knowledge of adverse consequences (e.g. failure to 
fulfil role obligations, use when it is physically hazardous). 
 
In both classifications, patients may also be variously classified as currently manifesting being 
in remission. The remission category can also be used for patients receiving agonist therapy 
(e.g. methadone maintenance) or for those living in a controlled drug free environment (APA 
1994). Furthermore in DSM-IV those in remission can be divided into four subtypes (full, 
early partial, sustained and sustained partial) on the basis of whether any of the criteria for 
abuse or dependence have been met and over what time frame. 
 
Since the 1970s heroin has been the most abused opioid and responsible for the largest share of 
drug-related diseases and deaths in the EU. Now this picture is changing and new recruitment 
into heroin use has fallen, which partly is because of shortage in availability, but also because 
other substances are taking its place, like fentanyl and buprenorphine. Especially this is the case 
for fentanyl in Estonia and buprenorphine in Finland (EMCDDA 2012a). 
 
 
2.1.4 Opioid abuse in Finland 
 
For long periods problematic drug abuse was dominated by amphetamines, and the use of 
heroin and other opiates became more widespread in Finland as late as the latter half of the 
1990s. In 1997 it was estimated that there were 1 526–3 261 opioid abusers and in 1998, 
around 1797–2656, which was 0.06%–0.09% of the population. The majority of abusers at this 
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time lived in the Helsinki metropolitan area: in 1995 in the metropolitan area, the number of 
opioid abusers was estimated to be 487–1 393, in 1997 around 921–1 996, and in 1998 around 
962–1 611 abusers, accounting for 0.17%–0.28% of the population aged 15–55 years (Partanen 
P. 2000). In 2005 the total estimated number of opioid abusers in Finland was 3700–4900 
meaning 0.13%–0.18% of the population (Partanen A. 2007). After 2005 the use of opioids has 
constantly risen and according to the latest surveys, the population aged 15 to 34, 0.6% have 
tried opioids (Hakkarainen P. 2011a; Hakkarainen P. 2011b). The major change in the opioid 
abuse occurred in 2001, following which mono-buprenorphine became the most misused opioid 
(Alho, Sinclair et al. 2007), originating mainly from France (Tacke 2002). In recent years, the 
situation has remained stable and no significant changes in the Finnish opioid abuse scene have 
occurred (EMCDDA 2012a; Varjonen V. 2012), but the number of opioid abusers seeking 
treatment has still risen throughout the 2000s (Väänänen 2010) 
 
Until now drug users in Finland were young by international comparison, but recent years have 
seen a change. In the past, the 20-24 years group was the largest, but now the 25–29 years and 
30–34 years age groups are bigger (Vuori E. 2003; Steentoft, Teige et al. 2006; Vuori E. 2006; 
Vuori E. 2009; Hakkinen, Launiainen et al. 2011; Simonsen, Normann et al. 2011). What is 
notable, though, is that the number of drug-related deaths has been increasing in Finland and 
especially deaths related to buprenorphine (Boyd, Randell et al. 2003; Vuori E. 2003; Vuori E. 
2006; Vuori E. 2009; Vuori E. 2012). In cases of fatal poisoning, prescribed opioids have 
become a major factor in Finland. Most drug-use-related poisonings are caused by 
buprenorphine, tramadol, methadone, fentanyl and codeine. Overdosing deaths caused by 
morphine, heroin or oxycodone rare. Overdosing is typically the result of multidrug use and 
drugs that have been injected or snorted. In 2010 fatal poisonings, opioid abuse was the main 
finding in 46 (out of 49 also including cases of medication use without abuse) cases of 
buprenorphine, in 27 tramadol (out of 47), in 16 fentanyl (out of 20) fatal poisonings, in 15 
methadone (out of 15) poisonings, in 5 codeine (out of 39) and in 2 (out of 2) morphine/heroin 
(Vuori E. 2012). The prominent role of alcohol and benzodiazepines as an additional substance 
and  co-occurring mental health disorders are typical of Finnish problem drug use (Hakkarainen 
2009; Tourunen J. 2009; Vorma 2009; Rönkä S. 2010; Tammi T. 2011) and are central to 
opioid overdose deaths (Hakkinen, Launiainen et al. 2011).  
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2.1.5 Buprenorphine in OMT 
 
Buprenorphine is a mu-opioid receptor partial agonist and kappa-opioid receptor antagonist, 
which means it binds to the receptors but does not produce maximum stimulation and there is 
an upper limit to the effect, even with increasing doses. Its physiological and intoxicating 
effects usually plateau at a sublingual dose of 4–8 mg. Because of this ceiling on its effect on 
respiratory depression and poor oral bioavailability, buprenorphine is safer in overdose than 
pure opioid receptor agonists. Respiratory depression from mono-buprenorphine or 
buprenorphine–naloxone overdose is less likely than from other opioids. However, significant 
respiratory depression can occur if buprenorphine is administered intravenously. 
 
Buprenorphine is highly bound to plasma proteins. It is metabolized by the liver via the 
cytochrome P450 enzyme system (CYP 3A4) into norbuprenorphine and other metabolites, 
which are excreted in the faeces (70%) and urine (30%). The half-life of buprenorphine is 
highly variable: 20–72 hours, with a mean of 36 hours. With stable dosing, steady state levels 
are achieved over 7-10 days. Peak clinical effects occur 1–4 hours after sublingual 
administration, with continued effects for up to 12 hours at low doses (2 mg), but as long as 72 
hours at higher doses (24–32 mg). The side effects are similar as for opioids generally. After 
cessation of use symptoms commence generally within 3–5 days of the last dose and can last 
for several weeks. The symptoms and signs of withdrawal from buprenorphine are similar to 
those found in withdrawal from other opioids, but withdrawal from buprenorphine is generally 
milder than withdrawal from methadone or heroin because of its slow dissociation from the m 
receptor. 
 
In Finland two formulations of sublingual tablets of buprenorphine are available. Mono-
buprenorphine (Subutex®, Reckitt Benckiser), in three dosage strengths of 0.4 mg, 2 mg and 8 
mg, and buprenorphine-naloxone (Suboxone®, Reckitt Benckiser), available in two dosage 
strengths of 2 mg buprenorphine with 0.5 mg naloxone, and 8 mg buprenorphine with 2 mg 
naloxone. The tablets take between 2 and 7 minutes to dissolve. Naloxone is a short-acting 
injectable opioid antagonist used in the management of opioid overdose to reverse the effects of 
opioids. It is poorly absorbed orally (under 10% bioavaibility) and so is used for medical 
reasons either intramuscularly or intravenously. It has a half-life of approximately one hour but 
continues to have 50% receptor occupancy at 2 hours after injection due to its receptor binding. 
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The parenteral to sublingual potency is 15:1 compared with the 2:1 ratio of buprenorphine 
(Amass, Ling et al. 2004). 
 
The addition of naloxone was designed specifically to decrease buprenorphine’s injectable 
abuse potential, especially by opiate abusers, and so discourage the diversion of buprenorphine 
from treatment. So the idea is that when taken sublingually, buprenorphine-naloxone is still an 
effective opioid; but when injected, the naloxone is predominant and can precipitate withdrawal 
(Eissenberg, Greenwald et al. 1996; Mendelson, Jones et al. 1996; Strain, Stoller et al. 2000; 
Stoller, Bigelow et al. 2001; Chiang and Hawks 2003; Harris, Mendelson et al. 2004; Strain, 
Moody et al. 2004). With persons abusing mainly buprenorphine intravenously this effect is not 
so clear, but still present depending on receptor occupancy (Harris, Jones et al. 2000; Comer, 
Sullivan et al. 2010). The difference of clinical effects of mono-buprenorphine and 
buprenorphine-naloxone are summarised in table 1. 
 
The abuse potential of buprenorphine has been recognized since its inception, and Finland, 
France, Australia and Great Britain have reported its misuse. According to the European 
Monitoring Centre for Drugs and Drug Addiction 12 out of 17 member states of the European 
Union reported the misuse of legal buprenorphine in 2004 (EMCDDA 2005) and this situation 
has not changed (EMCDDA 2012a). In the latest systematic reviews of literature the misuse of 
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Table 1: mono-buprenorphine vs. buprenorphine-naloxone by injection (unpublished, Leslie Amass oral 
presentation 2005 and Carola Fabritius 2008 oral presentation) 
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buprenorphine and methadone in the European Union has spread more and is recognized as a 
rising problem in many countries (Yokell, Zaller et al. 2011; Casati, Sedefov et al. 2012). The 
current European rates of misuse of medication used treatments for opioid dependence, mainly 
buprenorphine and methadone, in subjects involved in the open drug scene range from 5.6% in 
Portugal (Vale Andrade 2007) to 73% in Finland (Alho, Sinclair et al. 2007; Partanen A. 2007) 
and over 50 % for slow release morphine in Austria (Beer, Rabl et al. 2010). 
 
2.2. Treatment of opioid dependence 
 
Treatment of drug dependence can serve a multitude of purposes. Beyond reductions in drug 
usage, it can help the drug user to see his or her problems from a different perspective, improve 
self-reliance, and empower the individual to seek and effect changes in their life; it can even 
confer self-esteem and give hope. At the same time, it can provide access to physical and 
psychiatric care and social assistance, and provide for the needs of the patient’s family as well 
as those of the patient.  
 
In most cases, treatment will be required in the long-term or even throughout life. The aim of 
treatment services in such instances is not only to reduce or stop opioid use, but also to improve 
health and social functioning, and to help patients avoid some of the more serious 
consequences of drug use. Such long-term treatment, common for many medical conditions, 
should not be seen as treatment failure, but rather as a cost-effective way of prolonging life and 
improving quality of life, while supporting the natural and long-term process of change and 
recovery. 
 
2.2.1 Definition and general criteria of opioid maintenance treatment  
 
Treatment of opioid dependence has been defined by the World Health Organization (WHO) as 
a set of pharmacological and psychosocial interventions aimed at reducing or ceasing opioid 
use, preventing future harms associated with opioid use and improving the quality of life and 
well-being of the opioid-dependent patient (WHO 2009). There are two pharmacological 
approaches to opioid dependence treatment – those based on opioid withdrawal and those based 
on agonist maintenance (WHO 2009). 
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Detoxification is a gradual and managed medical withdrawal from the abuser’s regular level of 
drug use towards no drug use at all, using medications to help manage opioid withdrawal 
symptoms and cravings. Both methadone and buprenorphine are used in agonist assisted 
detoxification (Amato, Davoli et al. 2004a; Amato, Minozzi et al. 2004b; Digiusto, Lintzeris et 
al. 2005; Amato, Davoli et al. 2005a; Renzell and Capretto 2006, Shanahan, Doran et al. 2006). 
Buprenorphine detoxification can be completed in 1 or 2 weeks and methadone detoxification 
can take between 4 and 12 weeks. The duration depends on the starting dose, although it can 
vary widely. Also symptomatic medication can be used alone or beside agonist medication. The 
most common symptomatic medications are lofexidine (Strang, Bearn et al. 1999) and 
clonidine (Gossop 1988) often in combination with benzodiazepines. After detoxification, 
naltrexone, a long-acting, highly specific opioid antagonist, blocks opioid receptors so that the 
patient does not experience the usual effects of taking opioids, can be used for a small group of 
patients who are committed to achieving abstinence. They may benefit from naltrexone 
maintenance treatment (Adi, Juarez-Garcia et al. 2007; Lobmaier, Kunoe et al. 2011). Although 
a range of health benefits are often derived from detoxification, detoxification alone leads to 
lasting abstinence from drugs or significantly improved health and functioning for only a small 
minority of patients and many will relapse to illicit opioid use (Gandhi, Jaffe et al. 2003; 
Minozzi, Amato et al. 2006; Teesson, Havard et al. 2006; Minozzi, Amato et al. 2011). 
Maintenance pharmacotherapies can prove valuable in assisting these people to manage 
physical dependence, drug craving and compulsive drug use successfully (Bart 2012). 
 
Opioid maintenance treatment (OMT), often also referred to as Opioid substitution (OST) or 
opioid replacement (ORT) treatment, is defined as the administration of thoroughly evaluated 
opioid agonists, by accredited professionals, in the framework of recognized medical practice, 
to people with opioid dependence, for achieving defined treatment aims. Both methadone and 
buprenorphine are sufficiently long-acting to be taken once daily under supervision, if 
necessary. When taken on a daily basis they do not produce the cycles of intoxication and 
withdrawal seen with shorter-acting opioids (WHO 2004; WHO 2006; WHO 2011). 
 
Beside treatment there is also the approach of harm reduction. As the position statement from 
the International Harm Reduction Association states harm reduction refers to policies, 
programmes and practices that aim primarily to reduce the adverse health, social and economic 
consequences of the use of legal and illegal psychoactive drugs without necessarily reducing 
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drug consumption (IHRA 2010). Harm minimization philosophy involves accepting that 
despite all efforts to control supply and reduce demand, many people will continue to have 
access to licit and illicit drugs, and to use them in a way that puts them and society at risk of 
serious harm. Harm reduction includes services that promote safer drug use, e.g. needle and 
syringe exchange programs, safer injecting facilities, naloxone for overdose prevention, and 
information, education and communication programs for the clients also including peer 
outreach. Depending on local circumstances a range of drug dependence treatment options can 
be included, also containing opioid maintenance therapy. This means that harm reduction can 
be offered to drug abusers outside the treatment system but also as part of OMT for those 
patients who do not have the capability or will to cease drug use after entering treatment. They 
can be given by this approach the possibility to prepare themselves for more intensive and 
abstinence orientated treatment, while diminishing harms related to opioid abuse. 
 
Considering these different perspectives of OMT implementation treatment outcomes can also 
be divided into two main orientations. On one hand those emphasising harm minimizing 
treatment goals, like reduction of drug use, viral infections (HIV, HCV), overdoses and 
criminality, are those which can be more easily defined and measured. Then there are the more 
rehabilitation orientated treatment goals, like improvement of social and health issues, quality 
of life and employment, which are difficult to define and measure as they are mostly 
individually set. Depending on the approach chosen the treatment models are differently built, 
which makes it challenging to define, measure and compare their effectiveness  
 
2.2.2 General milestones of opioid maintenance treatment  
 
The first medically assisted treatments trials for opiate dependence started in the 1950s, when 
methadone was used to treat opiate withdrawal symptoms in the United States (Isbell 1948; 
Isbell and Eisenman 1948; Isbell, Wilker et al. 1948). Research on the issue followed and the 
first reports were published in the 1960s showing that relapse rates were high after leaving 
medically assisted treatment (Hunt and Odoroff 1962). In later studies (Wikler 1977; Dole 
1988) it was discovered that an ongoing, daily enough high dose of long-acting oral methadone 
(Dole and Nyswander 1965; Dole and Nyswander 1967) offered a number of beneficial effects, 
allowing opioid addicts to function more normally (Greenstein, Resnick et al. 1984; Kreek 
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1992). The findings of the first major studies were consistent and showed that methadone 
maintenance reduced the use of heroin, lowered death rates and criminality associated with 
heroin use (Joseph, Stancliff et al. 2000), and allowed patients to improve their health and 
social productivity (Novick, Pascarelli et al. 1988) which was also verified also by later reviews 
(Amato, Davoli et al. 2005b; Amato, Minozzi et al. 2008). Treatment could also diminish the 
transmission of infectious diseases associated with heroin injection, such as hepatitis C and 
HIV (Lavignasse, Lowenstein et al. 2002). Methadone Maintenance Treatment (MMT) was 
viewed as corrective therapy, rather than  healing opioid addiction. Methadone is the most used 
medication in the treatment for opioid dependence, but with the expansion of use, new 
problems arose: diversion and overdoses. These issues have been studied especially since the 
late 1990s and it seems that injection of treatment medication is a problem globally and related 
to all treatments, affecting from under 20% to over 50% of those studied (Darke, Ross et al. 
1996; Waldvogel and Uehlinger 1999; Humeniuk, Ali et al. 2003; Winstock, Lea et al. 2008; 
Christian Wickert C. 2009). Methadone used in treatment or diverted from treatment has also 
been linked to fatal overdoses (Heinemann, Iwersen-Bergmann et al. 2000; Perret, Deglon et al. 
2000; Vormfelde and Poser 2001), making this an important issue to be addressed in treatment. 
 
Buprenorphine was patented in the late 1960s for pain treatment, and being a partial agonist, it 
also generated interest for its possibilities to treat opioid dependence (Johnson and Fudala 
1992; Walsh, Preston et al. 1994). Substantial studies were published in the 1990s (Johnson, 
Cone et al. 1989; Johnson, Jaffe et al. 1992; Johnson, Eissenberg et al. 1995; Eissenberg, 
Greenwald et al. 1996; Fischer, Gombas et al. 1999) showing that it was useable and that the 
outcomes were clinically relevant (Elkader and Sproule 2005; Campbell and Lovell 2012). 
Further, in comparison with the golden standard of methadone, buprenorphine was shown to be 
effective and a real alternative (Strain, Stitzer et al. 1994; Ling, Wesson et al. 1996; Raisch, 
Fye et al. 2002; Heilig and Kakko 2003; Mattick, Ali et al. 2003; McCance-Katz 2004; Fareed, 
Vayalapalli et al. 2010) and also during pregnancy (Eder, Rupp et al. 2001; Johnson, Jones et 
al. 2001; Johnson, Jones et al. 2003; Schindler, Eder et al. 2003; Hytinantti, Kahila et al. 2008; 
Kahila, Stefanovic et al. 2008; Bakstad, Sarfi et al. 2009; Jones, O'Grady et al. 2009; Jones, 
Kaltenbach et al. 2010; Jones, Finnegan et al. 2012; Jones, Heil et al. 2012; Welle-Strand, 
Skurtveit et al. 2013). It was most widely used in France in treating heroin dependence, but 
increasing misuse was also reported (Agar, Bourgois et al. 2001; Vidal-Trecan, Varescon et al. 
2003). This same trend was then seen in other countries where buprenorphine became available 
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(EMCDDA 2005; Jenkinson, Clark et al. 2005; Alho, Sinclair et al. 2007; Cicero, Surratt et al. 
2007; Yokell, Zaller et al. 2011). This led to the development of a combination product 
containing buprenorphine and naloxone, which had a lower susceptibility to abuse (Robinson, 
Dukes et al. 1993) and was used less intravenously than mono-buprenorphine alone (Comer 
and Collins 2002; Degenhardt, Larance et al. 2009; Larance, Degenhardt et al. 2011a). Several 
studies have shown that the combination product is effective (Bell, Byron et al. 2004; Comer, 
Walker et al. 2005; Ling, Amass et al. 2005; Finch, Kamien et al. 2007; Mintzer, Eisenberg et 
al. 2007; Schackman, Leff et al. 2012), although buprenorphine is not as potent treatment 
medication as all doses of methadone (Ahmadi 2003c; Doran 2005; Connock, Juarez-Garcia et 
al. 2007; Mattick, Kimber et al. 2008). There are only few studies done on OMT of mainly 
buprenorphine addicted abusers and the treatment seems to be as effective as with heroin 
addicted patients regardless if they were treated with methadone or buprenorphine (Ahmadi and 
Ahmadi 2003a; Ahmadi, Ahmadi et al. 2003b). 
 
Opioid dependency treatment spread in the 1960s and 1970s and programs, mainly methadone 
and later also buprenorphine, were built up in the USA, Australia and Great Britain. The variety 
of treatments provided was broad and was mainly determined by the clinic and by local 
practice. In several countries, the preparation of guidelines was done mainly during the 1990s 
(NIH 1997) and by the WHO in 2009. Even though the latest treatment guidelines are based on 
evidence-based medicine, the treatment programs and medications used have nevertheless 
differed greatly in different countries, from heroin treatment in Switzerland to strict treatment 
policy countries like the Nordic countries (Skretting A. 2010).  
 
There are as many OMT models as treatment sites based on national and regional guidelines 
but also due to historical and cultural circumstances. This makes a comparison of the different 
treatment models as well as an evaluation of the outcomes of published studies somewhat 
challenging. An assessment of the research results often requires to some extent knowledge of 
clinical patient work in order to understand why an implementation in local circumstances is 
challenging, or to grasp the complexity of a patient’s addiction and related problems. As 
mentioned earlier, different perspectives on addiction itself also affect treatment models. Some 
are more medicine orientated and others also include psychosocial rehabilitation. When looking 
at Nordic countries this difference is detectable for example when comparing   Denmark, which 
has a strongly medically, somatic harm-reduction insight, and Sweden, which is clearly geared 
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more to a rehabilitation orientation (Skretting A. 2010). Heroin injection treatment, which has 
been accepted in Denmark since 2010, would at this point be unthinkable in Finland. These two 
examples signify quite aptly the wide variety of approaches to carrying out OMT. 
 
2.3 Milestones of opioid maintenance treatment in Finland 
 
Up to 1990, Finland did not have a severe opioid abuse problem and the main focus of drug 
policy was on minimizing drug availability and on harm reduction. Special care services for 
drug users were not considered necessary until then. However, increasing problems leading into 
the 1990s had led the Helsinki University Central Hospital and some non-profit organizations 
to start developing specialized services for opioid abusers, although this mainly meant 
psychosocial services. In 1996, only 5 patients were officially in methadone treatment 
(Hakkarainen P. 2005; Selin 2010). The attitude towards pharmacological treatment was clearly 
visible in the statement of the national alcohol and drug cooperation group given to the 1993 
opioid dependence treatment committee: “maintenance treatment for drug addicts should not be 
started in Finland because it does not treat the problem …but maintenance therapy in a way 
condemns the patient to a life-long drug addiction” (author’s translation)(Stakes 1993). With 
the rise of opioid-dependent persons and related harms in the later 1990s, pharmacological 
treatment was accepted as part of the Finnish drug policy; yet, the contradiction between non-
medical and pharmacological treatment approaches still exists today. 
 
In Finland, harm reduction has also its roots in criminal policy. Harm reduction has been 
especially disputed politically due to its presumed aim of liberalising the control of drug use. 
Opponents have feared that harm reduction practices such as needle exchange and substitution 
treatments would destroy the very foundations of the prohibitionist drug policy. With the 
changing drug abuse situation of the 1990s, the Finnish drug policy changed, leading to what 
has been called a dual track policy (Hakkarainen P. 2005). Studies on this change showed that 
rather than posing a threat to a prohibitionist drug policy, harm reduction has come to form part 
of prohibitionist drug policy. The implementation of harm reduction has implied an increasing 
involvement of the medical profession in addressing drug problems, while the criminal justice 
control of drug use has been intensified. Accordingly, harm reduction has not entailed a shift to 
a more liberal drug policy, nor has it undermined the prohibitionist penal policy. Rather, along 
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with the prohibitionist penal policy, it constitutes a new dual-track drug policy paradigm 
(Hakkarainen, Tigerstedt et al. 2007). This meant that measures such as syringe exchange 
services and maintenance treatment were initiated to counter drug-related public health 
problems, but, at the same time, the policies left intact restrictive drug policy measures built on 
a zero tolerance to drugs (Perälä 2012). 
 
Public attention focused on preventing diseases transmitted by injecting drug users in 1998, 
when the HIV epidemic began among Finnish drug users. Since 1997, health counselling 
centres have been established throughout the country and in the past years, their number has 
increased further. However, there is some variation in service provision depending on the 
facilities. The health counselling centres that exchanged needles and syringes to prevent 
infectious diseases are located mainly in cities with over 100 000 inhabitants and are available 
in more than 30 locations across Finland. According to available data, in 2011 the number of 
clients at health counselling was 1 134 with 84 586 visits and the number of syringes changed 
was 3.5 million (Tanhua H., Virtanen A. et al. 2011; EMCDDA 2012b).  
 
Current harm reduction services in Finland include outreach work and health counselling 
centres. The outreach work mainly involves street patrols, with the aim of mediating between 
drug users and the official care system. Peer work is emerging in several locations and focuses 
towards reaching the most excluded and most concealed groups of drug users. Health 
counselling centres are low threshold facilities catering for problem drug users, offering referral 
to treatment, case management, information on drug-related diseases and risks such as 
overdoses, needle exchange, as well as testing of infectious diseases and vaccinations against 
viral hepatitis A and B is offered and small scale health care (A-clinic Foundation 2000).  
 
2.3.1 Stipulations and statutes regulating OMT in Finland 
 
In Finland in the period 1995–1997, treatment was conducted based on the recommendations of 
the Ministry of Social Affairs and Health. In 1997, the Ministry issued a Decree that would 
more broadly govern treatment practices, with a maximum treatment period set at 3 months, 
although this was already extended to one year in 1998. In the Decree from 2002, treatment for 
one month or less was considered to be detoxification. Treatment which lasted longer than one 
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month was named either substitution if it aimed at a life free of drug use, or maintenance if it 
aimed at minimizing the harms and improving the life conditions of the person unable to stop 
abusing drugs. The evaluation for treatment had to be done in general hospitals, mainly 
psychiatric, or at the Järvenpää addiction hospital. The criteria for receiving treatment were 
tight and patients had to go through several detoxification treatments to establish they were 
unable to stop opioid abuse without OST. After the induction of treatment, they could be 
transferred to A-clinics if the patient’s condition was stable enough. This led to long waiting 
lists especially in the larger cities, despite the existence of a guaranteed statutory time frame to 
receive treatment within 6 months being established in 2005. The Decree was further revised so 
as to respond to the waiting lists.  
 
The main purpose of the latest amendment of the Decree (MSAH 33/2008; 
http://www.finlex.fi/fi/laki/alkup/2008/20080033 ) was to increase the supply of OST to better 
match need, while at the same time maintaining treatment-related controls so as to limit leakage 
of medicines into the black market. The 2008 Decree emphasized that treatment staging is based 
on disease severity in accordance with specialist care and primary health care services, that 
treatment evaluations and initiation are shifted from institutional care to outpatient units, and also 
that pharmacies are able to distribute the buprenorphine–naloxone combination. In 2009 only 31 
patients received reimbursements for their buprenorphine–naloxone medicine expenses. The 
number of patients receiving reimbursement increased threefold in 2010, involving 95 individuals 
at an expense of EUR 245 373. Since then, the rate of increase has slowed and in 2011 the 
possibility for pharmacy dispensing remains small scale in Finland, with only 123 patients 
receiving their medication from the pharmacy and 175 in 2012. This is below 10% of patients 
treated with the combination medication, even though it is now the most used preparation. There 
are no time limits on treatment whatsoever, and the 2008 Decree does not specify in detail the 
content of treatment. Treatment is rather perceived as a kind of framework, building on the best 
available knowledge. Methadone or buprenorphine can be used either in detoxification in order to 
get a person drug free or in substitution treatment. Substitution should aim at rehabilitation or 
reducing harms or improving the quality of life. Harm reduction is thus accepted as a goal, on a 
par with rehabilitation or detoxification. The decree memorandum emphasizes that treatment 
should follow the needs of each individual patient, and that pharmacological treatment alone is 
not enough. The decree claims that treatment has to be psychosocially assisted and every patient 
has to have an individual treatment plan. 
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At the same time as treatment regulations were loosening, a buprenorphine-naloxone 
combination drug became available in Finland in late 2004, introduced to lower the risk of 
misuse and was quickly adopted by the treatment units. Together with the introduction of the 
buprenorphine-naloxone product mono-buprenorphine was shifted under the special permission 
procedure. In this case it meant that the medication was only to be used for pregnant patients 
and for patients with a specific justification for it evaluated by the physician responsible for the 
treatment. The special permission has to be renewed annually. Buprenorphine-naloxone is now 
the most used preparation in Finland for patients treated with buprenorphine. 
 
2.3.2 Current status of opioid maintenance treatment in Finland 
 
The number of patients in treatment has been rising alongside the changes made in legislation 
(Figure 1), but is still low compared to other Nordic countries (Skretting A. 2010). Finland had 
been lacking an official register of patients in treatment, but it was established in spring 2012. 
Using several sources, including  about 90 treatment units in Finland, it was calculated that in 
summer 2012 2 436 patients were in treatment, of which 230 were treated with mono-
buprenorphine, 1 334 with buprenorphine-naloxone and 875 with methadone (THL 2012). 
 
 
 
 
Figure 1: Patients in OMT 1997–2012  
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The majority of patients are polydrug abusers (Onyeka, Uosukainen et al. 2012) and in 2010 
55% of patients seeking treatment at outpatient units abused opioids, of which were 32% 
buprenorphine compared to 2% abusing heroin (Väänänen 2011). Currently OMT is at a 
turning point in Finland due to increasing demand for treatment and reduced economic 
resources in the municipalities. As a result, many treatment units have tried to find new ways of 
producing treatments more effectively. At the same time, with municipalities aiming at better 
cost-effectiveness, they have sought competitive bidding for service provision as well as 
restricting access to treatment. For patients in treatment, the trend in municipalities seems to be 
towards transferring clients into harm-reduction treatment and narrowing it to just the supply of 
medicine, a trend that has significant risk factors associated with it (Vormfelde and Poser 2001; 
Jenkinson, Clark et al. 2005; Larance, Degenhardt et al. 2011a; Larance, Degenhardt et al. 
2011c; Johanson, Arfken et al. 2012). 
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3. Related research and aims of the study 
 
3.1 Research related to the current study 
 
The main research on buprenorphine has been on its efficacy, especially when compared to 
methadone (Fischer, Gombas et al. 1999; Ahmadi 2003c; Doran, Shanahan et al. 2003; Doran 
2005; Connock, Juarez-Garcia et al. 2007; Curcio, Franco et al. 2011). Only during the last few 
years has the spectrum of research broadened to involve the more clinical aspects of conducting 
treatment in different settings. Therefor only a limited number of the studies published have 
been relevant therefore to the research done in this study. 
 
Finland was the first country in the world, in late 2003, to see patients switched en masse from 
mono-buprenorphine to the combination formulation buprenorphine–naloxone. At that point 
the research available consisted of small scale studies concerning safety and effects (Fudala, Yu 
et al. 1998; Strain, Stoller et al. 2000; Stoller, Bigelow et al. 2001; Chiang and Hawks 2003; 
Mintzer, Correia et al. 2004), but no publications had yet emerged on switching from mono-
buprenorphine to buprenorphine–naloxone. The publication from Study I was the first, 
although later studies reported similar outcomes (Montesano, Zaccone et al. 2010; Stimolo, 
Favero et al. 2010). 
 
Before and during the switch from mono-buprenorphine to buprenorphine–naloxone, many 
clinics and prisons in Finland had begun crushing mono-buprenorphine medication before 
administering it to patients in order to minimize the risk of medication diversion. Clinical 
observations had suggested that crushed mono-buprenorphine tablets may yield the same or 
even better response than whole tablets (Muhleisen, Spence et al. 2003). At that point the only 
published data on bioavailability and pharmacokinetics of mono-buprenorphine concerned the 
liquid form of mono-buprenorphine (Strain, Moody et al. 2004; Compton, Ling et al. 2006; 
Compton, Ling et al. 2007). There were no published data concerning the pharmacokinetic or 
pharmacodynamic properties of crushed mono-buprenorphine tablets. Studies related to this 
issue of crushing medication since have been published, but they have been conducted with the 
buprenorphine–naloxone combination product and were more clinically orientated (Muhleisen 
P 2010). 
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Urine drug testing performed regularly or randomly plays an important role in substance abuse 
treatments. Drug testing can be used to measure compliance or treatment outcome, especially 
with opioid use discontinuation it is an essential treatment indicator, and can also ensure the 
safe administration of medication because concomitant drug abuse can resolve in OMT 
medication denial. That means that often patients have a high intention to manipulate their 
urine sample. Legally it is also crucial to ensure that the urine being analysed can undoubtedly 
be connected to the correct person. To ensure this, urine sampling is often strictly controlled, 
which can be a humiliating situation and ties up human resources. This strict control may 
negatively affect mutual trust, lower patient compliance and be a reason for professionals not 
use them as part of treatment (Dupouy, Bismuth et al. 2012) .  
 
A new marker method that makes supervision unnecessary was introduced by labelling the 
urine with modified polyethylene glycols, which are taken orally, quickly excreted through the 
kidneys, and do not occur in natural urine. They are detected only in the first urine after marker 
consumption. The different molecular weight marker solutions can be identified by LCM and 
linked to the person to whom it was given. In this procedure, only the consumption of the 
marker solution must be supervised. Drug testing is performed using normal, standard methods. 
Urine labelling has mainly been used in Germany as part of treatment and no international 
studies have been published on how this could enhance opioid maintenance treatment. The 
studies available considered the method (Gauchel, Huppertz et al. 2003; Huppertz, Gauchel et 
al. 2004) or reliability compared to conventional methods (Schneider, Ruhl et al. 2008). The 
publication of Study III was the first concerning patient compliance and financial 
considerations. 
 
Before the introduction of the buprenorphine–naloxone combination product, earlier studies on 
buprenorphine were mainly on efficacy, safety and tolerability of the product. Later, the main 
focus has been on the abuse liability of the formulation (Mammen and Bell 2009). Several 
studies on buprenorphine abuse have been published, most of them are short-term follow-ups 
(Robinson, Dukes et al. 1993; Comer, Sullivan et al. 2010;  Kemp 2012; Wish, Artigiani et al. 
2012), while long-term follow-up studies are rare (Smirnov and Kemp 2012). However there 
are few studies from countries or regions where buprenorphine is the most abused opioid, such 
as it is in Finland. 
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3.2 Aims of the study 
 
The principal aim of this study was to explore what factors could improve patient compliance 
and adherence to treatment, and thus may improve the OMT outcomes. 
 
The specific aims of this study were: 
 
1) to study the trends of drug and opioid abuse in Finland (metropolitan area), i.e. the trends in 
street price and means of administration of abused maintenance medications especially mono-
buprenorphine and buprenorphine-naloxone (IV). 
 
2) to study if the use of the buprenorphine–naloxone combination medication, which was 
designed to reduce diversion and intravenous misuse, would have an effect on medication dose 
and abuse, treatment outcomes and drug abuse (I, IV). 
 
3) to investigate if the different medication administration procedures (i.e. crushing the 
buprenorphine tablets) will affect to the pharmacokinetic and bioavailability of buprenorphine 
(II). 
 
4) to study if the new drug screening method (i.e. no visual control of the urine screen) could 
have an effect on patient compliance without compromising the reliability of the drug testing as 
part of treatment (III). 
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4. Methods 
4.1 Study participants 
 
Study I included the patient records from a total of 64 patients out of 87 patients treated with 
mono-buprenorphine in five treatment sites who fulfilled the criteria and were switched from 
mono-buprenorphine to buprenorphine-naloxone (Table 2). All patients who were switched  
 
were included in this study. The main reasons for exclusion were significant multidrug abuse 
and/or the decision of the responsible physician not to change the medication, no specific 
arguments were collected. Out of these 64 patients, 60 (93.8%) continued OMT with 
buprenorphine-naloxone into the follow-up period. Of these, 52 (81.2%) were male, 12 (18.7%) 
were female, and the average age was 29.9 years (SD ± 7 years). The mean mono-
buprenorphine treatment (days) was 63.3 (SD ± 363 days) and before medication change, a 
mean daily mono-buprenorphine treatment dose of 22.9 mg (SD ± 5.4 mg). At this point it was 
estimated there were around 400 patients were treated with mono-buprenorphine. 
 
 
 
 
 
 
Table 2: Participating Clinics and Patient demographics per Clinic for Study I. (Drug Rehabilitation 
Centre, Helsinki Deaconess Institute (HDL-01), Raahe Mental Health Clinic, Primary Health Care Centre (Raahe), Opiate Maintenance 
Polyclinic, Department of Drug Psychiatry, Helsinki University, Hospital, (HUS), Drug Rehabilitation Polyclinic at Tampere City, K-Clinic, 
A-clinic Foundation, (Tre-K-klinikka), Espoo A-clinic, A-clinic Foundation (Espoon A-klinikka) 
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Study II was conducted with 16 opioid-dependent persons out of whom 13 were in OMT either 
at the Espoo Treatment and Rehabilitation Centre, the Helsinki K-Clinic, or the Järvenpää 
Addiction Hospital. Three subjects were not in OMT, but fulfilled the other inclusion criteria 
(i.e. having a stable dose, 20–24 mg/day, for at least 4 weeks and no cannabis use 10 days prior 
to the study). The study persons had an average opioid dependence of 8 (SD ± 3.74) years for 
males and 7 (SD ± 4.45) years for females. One study subject discontinued treatment after the 
first day; the data for that subject were excluded from the analysis. Of the subjects, 10 were 
male (62.5%) and 6 were female (37.5%) and the mean age was 30 (SD ± 8.02) years and 25 
(SD ± 4.23) years for men and women respectively. For males the mean weight was 83 (SD ± 
7.86) kg and for females it was 59 (SD ± 16.31) kg. 
 
Study III included healthy volunteer patients undergoing treatment for their substance abuse 
problem at the Espoo Treatment and Rehabilitation Centre, A-clinic Foundation. Subjects were 
recruited into the study from the opioid dependence maintenance treatment unit (n = 29), the 
detoxification department (n = 26), and the outpatient department (n = 2). In the New labelling 
method (NM) group there were 20 patients in OMT, 11 in detoxification, and 1 as outpatient. 
The same numbers for the Traditional supervised urine sampling (TS) group were respectively 
9, 15, and 1. 
 
The subject population comprised 37 males (65%) and 20 females (35%). There were no 
gender differences between the two study groups. The mean age was 36 years (SD ± 8.76) in 
the New marker group (NM) test group and 40 years (SD ± 10.16) in the traditional supervision 
(TS) test group. The average time in treatment was 32.4 months (SD ± 35.69) in the NM group 
and 16.5 months (SD ± 30.43) in the TS group. In the NM group, one study subject 
discontinued the study after three samples, and another discontinued the study after three 
samples but returned to the study 2 days later. Both completed the study questionnaire. 
 
Study IV participants were volunteer persons using harm reduction services in the Helsinki 
metropolitan area over 2-week periods in the years 2005–2010 (excluding 2009). In total 1507 
individuals completed the questionnaires. The mean response rate was 50.8% (calculated as the 
return rate % of the individuals who visited the service units during the study period) and 
ranged from 45.4 (2008) to 58.2% (2005). Of the respondents, 1023 were male (68%) and 478 
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(32%) were female. The average age in 2005 was 27.8 (SD ± 6.9) years; by 2010 it had risen to 
31.9 (SD ± 8.6) years (t=-4.234 df=488 ,  see table 3 for detailed information. 
 
 
 
Table 3: Demographics for Study IV (unpublished from study IV) 
 
 
4.2. Ethical considerations and funding 
 
The studies were approved variously by the independent Hospital District of Helsinki and 
Uusimaa Ethical Committee, the Finnish National Agency of Medicines, the THL Ethics 
Committee and the Ethical Committee of the A-Clinic Foundation. Data protection was ensured 
throughout in accordance with the regulations governing the National Institute for Health and 
Welfare (and previously the National Public Health Institute). All the studies were conducted 
according to the ICH Guidelines for Good Clinical Practice and the 1964 Declaration of 
Helsinki. 
 
Study I permissions 
Independent Hospital District of Helsinki and Uusimaa Ethical Committee notification (given 
24.8.2004) 
 
Study II permissions 
Independent Hospital District of Helsinki and Uusimaa Ethical Committee (502/E3/2003) 
The Finnish National Agency of Medicine (KL# 22/2004) 
 
 
2005 2006 2007 2008 2010
n 176 260 411 384 276
male 131 170 278 258 186
female 45 89 133 124 87
mean age 27,8 (SD ± 6.9) 29,7 (SD ± 8) 30 (SD ± 7.80) 31 (SD ± 8) 31,9 (SD ± 8.6)
Years of opioid iv misuse 7,3 (SD ± 4.9) 7,6 (SD ± 4.53) 8,6 (SD ± 6.47) 8,8 (SD ± 6) 9,8 (SD ± 6.66)
Years of mono-buprenorphine iv 
misuse 4,17 (SD ± 2) 4,8 (SD ± 2.50) 5,4 (SD ± 3.13) 5,5 (SD ± 3) 7,2 (SD ± 4.03)
Years of buprenorphine-
naloxone iv misuse N.A. 1.7 (SD± 1.7) 1.8 (SD ± 0.9) 2.4 (SD ± 2.2) 4.0 (SD ± 3.4)
P<0. 001
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Study III permissions 
Independent Hospital District of Helsinki and Uusimaa Ethical Committee (347/13/03/00/08) 
 
Study IV permissions 
National Public Health Institute (KTL 6/2004) 
 
All the studies were coordinated and funded  by the Department of Mental Health and Alcohol 
Research of the National Public Health Institute in Finland (or from 2009, the National Institute 
for Health and Welfare).  
 
Kaarlo  Simojoki has received lecture fees from  Schering- Plough, MSD,  Boehring-Ingelheim, 
Helsinki  city,  GlaxoSmithKline, Ruma  Gmbh,  Orion, RBP,  Lundbeck, Professio, HUS,  has 
received paid congress trips from Schering-Plough, Reckitt Benckiser Pharmaceuticals Finland, 
Azanta, Lundbeck  and  has  been  an  OMT-HCV  advisory  board member at Schering-Plough 
until 2010. 
 
4.3 Study designs and methods 
 
Study I was retrospective, involving data collection from opioid-dependent patient’s records 
who had undergone a switch from mono-buprenorphine to buprenorphine/naloxone and having 
a mono-buprenorphine dose of at least 12 mg/day prior to change. Data were collected using 
structured data collection forms and possible missing data was collected afterwards from every 
site. Five treatment centres were randomly chosen from 20 treatment centres that were using 
mono-buprenorphine. Two of the centres are located in Helsinki (HDL, HUS), one in the 
district of Southern Uusimaa (Espoon A-klinikka), one in central Finland (Tampere), and one 
in northern Finland (Raahe). At the time the centres were selected both Raahe and HDL 
announced that they had more than 10 patients being treated with buprenorphine, but at the 
time of data collection they had less than 10 patients who fulfilled the inclusion criteria for the 
study. 
 
Data were collected for three days during the week of the medication switch and at 1, 2, 3 and 4 
weeks following the transfer to the new formulation. The earliest date of switch from mono-
  
39 
 
buprenorphine to buprenorphine-naloxone was 5 November 2003 and the latest date of switch 
was 4 December 2004. Information gathered was mono-buprenorphine dose on the day the 
transfer was recorded, and the buprenorphine-naloxone doses used during the four weeks 
following the switch once per week. Drug misuse measures as well as length of non-opioid 
drug use were also recorded. The frequency of clinic visits, and therefore prescription size of 
take-home medication for continued use, was based on the usual clinic practice at least once 
weekly. All clinics conducted urine tests at least once a week. Adverse events considered as 
being associated with the switch from mono-buprenorphine to buprenorphine-naloxone on the 
day of the switch, days 2 and 3, and weeks 1 to 4 following the switch were recorded. The same 
adverse events four months after the study period were also collected. The Medical Dictionary 
for Regulatory Activities (MedDRA) coding was followed. Overall patient complacence 
(patient satisfaction with the switch to buprenorphine-naloxone) and compliance (related to 
regular visit attendance, appropriate medication intake, and history or signs of misuse), with 
reasons for non-compliance, were recorded on each of the weekly visits to the clinic before and 
after the switch. The data gathered from patient records prior to the switch (mono-
buprenorphine dose, drug misuse and frequency of clinic visits) is considered as baseline data. 
The data collection was repeated four months post-transfer (follow-up period) with 6 specified 
questions a) current treatment status: still in treatment/not in treatment b) current treatment 
medication: Suboxone®, Subutex®, methadone, other (specify) c) misuse activity of opioids: 
any signs of misuse, yes/no d) patient satisfaction: yes/no e) adverse events: any since the 
primary data collection f) abuse of Suboxone®: if yes specify patient’s experience. All answers 
had to be specified and findings described. 
 
Primary outcomes of this study were a) dose of buprenorphine before and after switching to 
Suboxone®, b) weaning (dose adjustments) and noticed adverse reactions during the 4-week 
study period and the follow-up period and c) physical signs and patient reports of intravenous 
misuse of buprenorphine. Secondary outcomes were a) knowledge of opiate (heroin)/opioid 
abuse evident from urine tests, b) patient satisfaction/dissatisfaction with buprenorphine-
naloxone during the 4-week study period and at the end of the follow-up period and c) 
frequency of patient’s visits to the treatment clinic before and after the switch to 
buprenorphine-naloxone d) current treatment status and medication at the end of the follow-up 
period. The outcomes were summarised for all patients, by study site and by treatment phase. 
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Study II had a double-blind, double-dummy, randomized crossover design that compared 
crushed and whole mono-buprenorphine tablets on a range of pharmacokinetic variables. All 
participants were stabilized on a dosage of 24 mg mono-buprenorphine per day for at least 7 
days prior to blood sampling. Subjects were then randomized into 2 groups. They received 
either crushed or whole active or placebo tablets according to the study plan. The blind was 
maintained by using placebo and active 8 mg mono-buprenorphine tablets, with neither the 
study doctor nor the patient being aware of whether the crushed or whole tablet was the active 
drug. Crushing of the tablets was always performed with a commercially available tablet 
crusher and the tablet dissolution time, which was defined as the number of minutes that 
elapsed between placing the tablets in the patient’s mouth and the point at which the tablet was 
no longer visible to the study personnel, was measured. Blood samples were taken prior to the 
administration of the study medication (baseline) and at 30, 60, 90, 120, 180, 240 and 360 min 
after dosing. The next morning, a 24hour blood sample was taken. All Gas chromatography-
mass spectrometry (GC-MS) analyses were done at the accredited laboratory of the National 
Institute for Health and Welfare. Drugs were extracted from basic solutions (pH approx. 9) by 
liquid-liquid extraction using toluene containing deuterated buprenorphine as an internal 
standard. After evaporation of the solvent, the extracted compounds were silylated by MSTFA 
(N-methyl-N-trimethylsilyl-trifluoro- acetamide). The samples were analysed with the Agilent 
Network GC-MS 6890/5973 instrument. Separation was carried out on a DB-35MS (30 m/0.32 
i.d./0.25- m film) fused silica capillary column, using helium as a carrier gas. The oven 
temperature program was increased from 180° C (1 min) to 340° C (4 min). Selected ion 
monitoring was used in the electron impact mode and ions 450 and 482 for buprenorphine; 468, 
500, 510 and 542 for norbuprenorphine; and 454 for deuterated buprenorphine were followed. 
The method was found to be sensitive, and the limit of quantization was 0.5 ng/ml for both 
buprenorphine and norbuprenorphine. The accuracy and precision of the method at the 
concentration level of 0.5 ng/ml were as follows: 9.4% (buprenorphine) / 4.6% 
(norbuprenorphine) for accuracy; 5.3 (buprenorphine) / 13.0 (norbuprenorphine) intraday assay, 
and 7.9 (buprenorphine) / 27.7 (norbuprenorphine) interday assay. The linearity range for both 
analyses was 0.5–15 ng/ml. This GC-MS method has been accredited by the Finnish 
Accreditation Service. 
 
The extent of opioid craving (Rosenberg 2009) was measured with a visual analogue scale 
(VAS), a psychometric response scale, which is a measurement instrument for subjective 
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characteristics or attitudes that cannot be directly measured (Hasson and Arnetz 2005). When 
responding to a VAS item, respondents specify their level of agreement to a statement by 
indicating a position along a continuous line between two end points. In this study participants 
rated the current intensity of their desire to use opioids from 0% (none at all) to 100% (more 
than ever). Opioid withdrawal symptoms were measured with the Subjective Opioid 
Withdrawal Scale (SOWS) (Handelsman, Cochrane et al. 1987; Gossop 1990). It is a self-
administered scale for grading opioid withdrawal symptoms and contains 16 symptoms whose 
intensity the patient rates on a scale of 0 (not at all) to 4 (extremely). The total scores range 
from 0 to 64 and mild withdrawal is considered to be a score of 1 – 10, moderate withdrawal is 
considered to be a score of 11 – 20 and severe over 21 scores. 
 
Primary outcomes of this study were  buprenorphine and norbuprenorphine pharmacokinetic 
parameters (C max, T max, AUC 0–4, AUC 0–24) of whole and crushed buprenorphine tablets. 
Secondary outcomes were pharmacokinetic parameters, including a) opioid withdrawal, as 
measured by the SOWS, b) opioid craving, as measured by the VAS, c) patient reports of 
possible adverse events and d) dissolution time of the whole versus crushed tablet, 
 
In Study III the subjects were randomized into two groups, the new marker method (NM) group 
and the traditional supervised (TS) sampling group. The study was conducted from 11.11.2008 
to 15.01.2009.  
 
In the NM group three different molecular weight markers were used and were given to the 
patients in a random fashion. The patients did not know the molecular weight of the solution 
they received. The marker vials, which contained 30 ml of the marker solution, were 
individually labelled. The marker was then mixed with approximately 100 ml of a sweet soft 
drink. Patients were asked to drink this solution 30-45 minutes prior to the delivery of urine. 
They were then allowed to urinate without supervision in the clinic or to take the urine test tube 
home and return it to the clinic within 1 week. After patients submitted the urine sample (20–50 
ml), the test tube was directly identified with a bar code label according to the routine 
procedure of the Central Laboratory Cologne. An accompanying order sheet was labelled with 
the patient’s name, the type of drug analyses requested, and the type of marker substance that 
was used. Samples were then sent to the Central Laboratory Cologne via shuttle service twice a 
week. Prior to shipping, the samples were stored in a refrigerator in a closed room. At the 
  
42 
 
Central Laboratory, order sheets were read by an automatic chart reader. Urine samples were 
centrifuged and directly transported to the analytical site for determination of marker 
substances and drug analyses by gas chromatograph detector  (Hewlett Packard, 5790 Series II, 
connected with a mass selective detector 5972; Hewlett Packard, Palo Alto, USA). 
 
In the TS test group, direct inspection of patients while urinating was conducted by trained 
clinical staff. The patients were asked to provide the sample using a test toilet, which had 
mirrors on the walls to ease supervision. Patients were asked to undress sufficiently, which was 
determined by the person supervising. After depositing the sample in the test tube, the patient 
closed the test tube and gave it to the supervisor. The urine was then quick screen tested in a 
separate closed room immediately or later during the same day; in the latter case, the sample 
was stored in a refrigerator. The screening test used is manufactured by SYNTRON 
Bioresearch, Inc., an FDA-registered medical device manufacturer, and was supplied by 
Labema. Only if it was needed the quick screen result was confirmed by LCMS. 
 
Following urine testing, subjects in both groups completed a questionnaire. The information 
gathered included when the urine test was requested, where it was performed, and whether the 
situation was pleasant or unpleasant, which was asked and recorded by the personnel soon after 
each urine test. Each subject was asked to deliver a urine sample once or several times, 
depending on the treatment phases and visits. In the NM test group, information was also 
gathered on the given marker, whether the patient took the urine test at home, and, if so, 
whether the sample was delivered. A questionnaire was created that included background 
information, two questions measuring satisfaction on a likert-type 1-6 scale (Jamieson 2004; 
Pell 2005; Carifio and Perla 2008; Norman 2010), and the patient’s preferred testing system. 
The questionnaire was given to the subjects at the end of the study period, or earlier if the 
patient was unlikely to return to treatment during that period, for example, if the patient was in 
detox treatment. 
 
All personnel members who were involved in taking urine samples for the study (n = 10), out 
of whom 7 worked in OMT, 2 in detoxification, and 1 at outpatient clinic, completed a 
questionnaire. It included 4 background information questions, three likert-type 1-6 scale 
questions, four multiple-choice questions and two open-ended questions. All employees were 
experienced in the addiction field and were, on average, 40 years old. All of them had had a 
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long experience in collecting TS urine tests and 60% (n = 6) had performed over 20 NM tests, 
10% had performed between 10 and 20 tests, 20% had performed between 5 and 10 tests, and 
10% had performed less than 5 tests. 
 
The primary outcomes of this study were a) return rate of the urine samples, b) detected 
manipulation of urine samples and c) patient satisfaction with the used method. The secondary 
outcomes were a) employee satisfaction, b) estimated time used for the sampling and 
controlling procedure, and c) economic trade-off. It was also intended to see if it would be 
possible to allow patients to give their urine sample outside the clinic, opening new 
opportunities for flexible testing. 
 
Study IV was conducted by a questionnaire consisting of multiple-choice and fill-in-the-blank 
questions at harm reduction services in the Helsinki metropolitan area over 2-week periods in 
the years 2005–2010 (excluding 2009). Survey completion was voluntary and anonymous; the 
return or non-return of the survey had no influence on the services provided by the centre. The 
centre visitors were instructed to fill out the questionnaire only once. Personnel at the harm 
reduction unit did not receive the completed surveys but directed participants to place the 
surveys in a box accessible only to the investigators. No identifying information was obtained. 
 
The questionnaire consisted of two parts, of which the first part was for all drug abusers; the 
second was to be answered only by buprenorphine abusers. The number of answers obtained 
were reported individually in the result section. Twelve questions were asked on all study 
surveys since 2005, and for that included into the study. New questions were added (five in 
2007,  and two more in 2010)  in subsequent  years and have also been used in the analyses,
 because  they  gave  important  new  information. Some  survey  questions  required two part
 responses; for example, “At what age did you start using drugs, and when was the first  time
 you injected?” If only one part was completed, neither part was included in the analysis. 
 
The questionnaire included background (gender and age), first intravenously abused drug and 
opioid. Two questions focused on the patterns of drug: 1) What is currently the drug you most 
frequently use; 2) Which drugs do you use in addition to the previously mentioned drug. 
Responses were categorized into 7 subgroups: a) all buprenorphine products, b) all 
amphetamine/methamphetamine drugs, c) heroin or morphine, d) MDMA, MDA, MDEA, 
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MBDB or ecstasy, e) cocaine, f) oxycontin, and g)other drug (if not fitting into classes a-f). For 
both for mono- buprenorphine and buprenorphine-naloxone was asked the duration of 
intravenous abuse, frequency and dose of abuse, route of abuse, street price paid for an 8mg 
tablet, and from where the buprenorphine was obtained. HCV infection prevalence and demand 
for entering opioid maintenance treatmen were asked. For further analyses of buprenorphine as 
first abused intravenous opioid the respondents were divided into 6 subgroups, defined by the 
researcher, according to the length of their intravenous opioid abuse: less than one year, 1–3 
years, 3–5 years, 5–7 years, 7–9 years and over 10 years. The ranges for the subgroups were 
chosen upon clinical experience and to ensure big enough samples from the data for analysis. 
 
Primary outcomes of this study were a) first intravenously abused opioid b) duration of mono-
buprenorphine and buprenorphine-naloxone abuse c) changes in abused buprenorphine 
prevalence d) changes in buprenorphine street prices. 
 
4.4 Statistical analyses 
 
In all the studies the main results were reported either as percentages or total number of 
respondents and with means ± SD if not otherwise specified. Because the studies differ from 
each other, the analysis is clarified below. 
 
In Study I descriptive statistics were used to summarise the data. The protocol stated that a Chi 
squared test would be conducted to determine the statistical significance of trends in changes of 
test variables. It was later determined by the principal investigator that this test was not 
necessary with the data collected. Demographics and baseline parameters were summarised by 
study site and by treatment phase, for all patients. Efficacy analyses included doses of 
buprenorphine (in the form of mono-buprenorphine or buprenorphine-naloxone before and after 
attempted switch to buprenorphine-naloxone).  
 
In Study II, the subject, treatment, time and plasma concentration data were manually entered 
into an Excel 97-2003 spreadsheet. These data were imported into WinNonlin Pro version 5.0.1 
(Pharsight Corp., Mountain View, Calif., USA). Standard non-compartmental pharmacokinetic 
methods were used to estimate Maximum observed serum drug concentration (Cmax), time to 
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maximum concentration of drug in serum (Tmax) and The Area under the Concentration - time 
curve over 24 hours (AUC 0–24). The AUC 0–24 and Cmax were analysed on a log scale using 
an ANOVA model to assess bioequivalence between Form I (the test) and Form V (the 
reference). The analysis of variance for a 2-way crossover design included the following fixed 
factors: sequence, period and form, and subject (sequence) as a random effect. The two 1-sided 
t-test hypotheses were tested at the 0.05 level of significance by constructing 90% confidence 
intervals (CI) for the ratio of test-to-reference means. The two test treatments were considered 
bioequivalent if the 90% CI of the relative mean C max and AUC 0–24 of the test to reference 
were within 80%–125%. 
 
For Study III, subject and staff background information and questionnaire responses were 
manually entered into a Microsoft Excel 97-2003 spreadsheet and then analysed using Excel 
functionality calculating mean values and SD. Survo versio 3.35 was used to calculate Student's 
t, chi2, df and p-value (one-sided test) 
 
In Study IV, the number of respondents differs from question to question as participants were 
free to complete any or all portions of the survey. The number of answers obtained was 
reported individually in the result section. The results, Student's t, chi2, df and p-value (one-
sided test), were calculated by using the Survo version 3.35 program and were also partly 
entered manually into a Microsoft Excel 97-2003 spreadsheet and then analysed using Excel 
calculating mean values and SD. 
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5. Results 
5.1 Trends of opioid abuse in Finland 
 
The results are based on Study IV investigating the trends of opioid abuse in Finland. The 
results were compared to published results (original data was not available) of the RISKI study, 
which was conducted from 2000–2002 on injecting drug users visiting harm reduction services, 
describing their background and drug use on the basis of baseline interviews (Partanen A. 
2004a). According to the RISKI results, six month prior to the study, 17% misused mono-
buprenorphine sublingually, 17% intranasally and 67% intravenously. The administration route 
for heroin was 14% by smoking, 8% by inhalation and 50% by intravenous injection (n = 494). 
 
In the 2005 (n = 153) questionnaire, the average intravenous opioid misuse had lasted 7.3 years 
(SD ± 4.9); which steadily increased over the next years to an average of 9.8 years (SD ± 6.7) 
in 2010 (n = 226) (t=-4.005 df=377 P<0.001). 
 
The onset age was not asked in the 2005 survey, but the mean onset time of opioid abuse was 
18.3 years (SD ± 4.8) in 2007 (n = 382), 18.07 years (SD ± 4.5) in 2008 (n = 326) and 18.6 
years (SD ± 5.1) in 2010 (n = 245) (t=-1.365 df=569 P=0.0863 ) (Table 4). 
 
 
 
 
 
age (years) first time drugs abuse (n = 211) first time drugs iv abuse (n = 244) 
< 10 3.2% N.A 
11- 15 55.2% 23.4%  
16-17 20.0 % 21.7 % 
18- 20 15.4 % 30.3 % 
> 20 6.2 % 2.6% 
 
Table 4: First abuse and intravenous abuse of drugs (not opioids) in 2010 (unpublished from study IV) 
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The first intravenously abused drug was inquired of since 2007, when 60.2% (n = 344) stated 
that heroin or morphine was their first intravenously abused opioid, and 30.5% abused 
buprenorphine. In 2010 (n = 234) the percentage starting intravenous drug use with heroin or 
morphine had fallen to 51.3%. Buprenorphine as the first intravenously abused drug increased 
by 13.9% (44.4% in 2010)(Chi2=14.81 df=3 P<0.0020). In 2007 9.3 % of respondents 
answered having started with another drug (non-opioids); this percentage decreased to 4.3% in 
2010 (Chi 2=0.736671 df=1 P=0.3907) (Figure 2). 
 
 
 
 
 
Figure 2: First intravenously abused opioid (published in Study IV) 
 
 
 
In 2005 and 2006 heroin/morphine was the third most misused intravenous substance, but since 
2007 it has been passed by the category “other drug”, which includes among other mainly 
benzodiazepines and so-called designer drugs, with annual frequencies varying between 21.3% 
and 44.9%. Heroin/ morphine were abused in 2005 by 2.3%; this increased to 11.7% in 2007 
and has since declined to 8.3% in 2010 (Chi2=49.6211 df=20 P<0.001) (Figure 3). 
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Figure 3: Two most abused intravenous drug groups and the use heroin/morphine (unpublished from 
Study IV) 
 
Data not included in Study IV, but presented in this thesis from the 2007 (n = 314), 2008 (n = 
275) and 2010 (n = 210) surveys gives a more detailed picture concerning intravenously 
misused opioids. As assumed, based on earlier studies (Alho, Sinclair et al. 2007), heroin is the 
first abused intravenous opioid for the clear majority (50–70%) in the population having abused 
opioids over 7 years and in the under 1 year group for less than 0.9%–3.4%. When looking at 
the data for buprenorphine it is the most largest (23%–34%) first intravenously abused opioid 
for the abuser group with a 3–5 year history of intravenous abuse. In the group with less than 1 
year intravenous abuse buprenorphine is the first intravenous abused opioid for 15% in 2007 
and in 2010 for 10.3% of the respondents (Chi2=11.9823 df=5 P<0.0350). Based on the data it 
seems that the number of new opioid abusers having buprenorphine as their first intravenously 
used opioid has started to decrease since 2007 after being at its highest before 2004, but due to 
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the small responder number no reliable conclusion can be made (Chi2=1.16339 df=2 
P=0.5589) (Figures 4–5). 
 
 
 
 
Figure 4: First abuse intravenous opioid: heroin (unpublished data based on data from Study IV) 
 
 
 
 
Figure 5: First abuse intravenous opioid: buprenorphine (unpublished data based on data from study IV) 
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5.1.1 Abuse of mono-buprenorphine and buprenorphine- naloxone 
 
The duration of intravenous abuse of mono-buprenorphine in 2005 (n = 173) was 4.2 years (SD 
± 2); in 2010 (n = 201) it was 7.2 years (SD ± 4) (t=-8.954 df=372 P<0.001). The duration for 
buprenorphine-naloxone was 1.7 years (SD ± 1.7) in 2006 and 4 years (SD ± 3.4) in 2010  ( t=-
4.928 df=153 P<0.001). 
 
The majority reported daily intravenous use: 81.7% in 2005 (n = 148) and 74.3% in 2010 (n = 
187). There was no significant change in frequency of daily mono-buprenorphine injection 
from 2005 to 2010. Most injected 2-4 times daily, reported by 67.7% in 2005 and 74.1% in 
2010 (Chi2=23.7943 df=16 P=0.0940). 
 
In 2005 (n = 145), the 12-month prevalence for buprenorphine-naloxone abuse was 67.3% and 
had been tried once by 23.4%, more than twice by 35.8% and for at least two weeks regularly 
and frequently by 8.1%. In 2010 (n = 174) the amounts were correspondingly 8%, 56.7% and 
14.4%. (Chi2=27.2508 df=3 P<0.001).  The prevalence for the responders’ lifetime 
buprenorphine-naloxone abuse in 2005 was 68%, and in 2010 80.5% (Chi2=6.24875 df=1 
P<0.001). 
 
The abuse route of buprenorphine-naloxone was changed during the study years. In 2005 (n = 
111) 60.4% misused intravenously, 4.5% nasally and 13.5% sublingually while 21.6% reported 
mixed ways (asked only in 2006). This was changed by 2010 (n = 140) when 69.3% misused 
intravenously, 24.3% nasally and only 6.4% sublingually (Chi2=40.8666 df=12 P<0.001). 
 
One means for measuring a drug’s monetary value to subjects is to determine the street price of 
the drug and this was asked in all surveys. In 2005 (n = 176) the mean street price for mono-
buprenorphine was 28 Euros; it had increased by 53.2 % to 42.9 Euros in 2010 (t=-15.12 
df=329 P<0.001). The corresponding average price of buprenorphine-naloxone was 12.3 Euros 
in 2005 and  increased by 103.2% to 25 Euros in 2010 (t=-11.49 df=223  The price 
of buprenorphine-naloxone was 56% lower than mono-buprenorphine but in 2010 the price 
difference had declined to 41.7%. During the same time the daily mean dose of mono-
buprenorphine dropped by 22.9% from 7.0 mg to 5.5 mg (t=-3.234 df=361 P=0.0007). The 
 P<0.001).
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daily average dose for buprenorphine-naloxone (asked since 2006, n= 182) decreased by 36.6% 
from 8.2 mg to 5.2 mg in 2010 (n= 105) (t=-3.194 df=165 P=0.0008 Figure 6). 
 
  
Figure 6: Street price of mono-buprenorphine and buprenorphine–naloxone (published in Study IV) 
Correlations between price and use mono-buprenorphine -0.6232 and buprenorphine–naloxone 
-0.8171 
 
 
Respondents were asked for the first time in 2010 where they obtained their buprenorphine. For 
mono-buprenorphine (n = 161), the majority (91.3%) reported buying it from a street dealer, 
22.4% from a person attending official substitution treatment, and 8.7% imported it themselves 
from abroad. For buprenorphine-naloxone (n = 125), the corresponding numbers were 68.8% 
bought from a dealer, 49.2% from a person in substitution treatment, and only 2.4% brought it 
abroad (Chi2=24.3302 df=2 P<0.001). 
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The number of respondents being in OMT was also looked at and in 2006 the questions were 
answered by 141 clients (80.1%) and in 2010 by 192 (69.6%). Out of these, 8 (5.7%) were in 
treatment in Finland in 2006 and 29 (18.8%) in 2010 (Chi2=18.1778 df=3 P=0.0004). In 2006 
24 (14.9%) were in treatment abroad, but in 2010 only 2 (1.3%) abroad (Chi2=44.7355 df=3 
P<0.001) The number of respondents who wished to enter OMT programs was 43% in 2006 (n 
= 112) and 64.1% in 2010 (n = 123) (Chi2=9.84766 df=3 P=0.0199). In 2010, of the remaining 
84 respondents, 45.2% had fulfilled the criteria for OMT and lined up treatment, 26.2% had not 
been accepted for treatment, and 28.6% had repeatedly attempted to enter treatment but had not 
fulfilled the criteria. There was no clear correlation between the time in years of opioid 
intravenous use and wish of entering OMT, being -0.0413 (t=-0.541 df=171 P=0.2947). 
 
 
5.2 The use of buprenorphine-naloxone combination in OMT 
 
5.2.2 Transfer from mono-buprenorphine to buprenorphine-naloxone combination 
 
In Study I, 58 patients (90.6%) switched from mono-buprenorphine to combination at the same 
dose of mono-buprenorphine that they had been receiving as mono-buprenorphine alone. One 
patient was transferred with a higher buprenorphine-naloxone dose (2 mg), two with lower 
doses (2–4 mg) and three patients were "titrated" with daily increases of buprenorphine-
naloxone (patient anxiety over the transfer) up to the previous mono-buprenorphine dose. Out 
of the 60 patients finishing the four-week study period 53 patients (82.8%) were treated 
throughout the study period with only buprenorphine-naloxone (Table 5), and 46 of these 
(71.9%) were maintained at the same dose of buprenorphine-naloxone. During the four-week 
period, four patients (6.3%) had dose reductions and one patient (1.6%) had a dose increase 
with buprenorphine-naloxone. Two patients (3.1%) had temporary dose changes during the 
four-week study period and seven patients had titrated dosing (2–3 day interval in increase). At 
the four-month follow-up out of the 26 patients continuing treatment with buprenorphine-
naloxone, 10 patients (38.5%) were treated with the same dose of buprenorphine-naloxone, 15 
patients (57.7%) had dose reductions (2 mg–16 mg), and one patient (3.8%) had a dose increase 
(2 mg). 
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a: Patient returned to treatment during follow-up after discontinuing during the 4-week study period. 
b: Patients may have had more than one reason for discontinuation. 
c: All 5 patients switched to other centres. Two of the patients were switched to methadone prior to 
switch to other centre. 
 
 
Table 5: Reasons for discontinuation of buprenorphine-naloxone (unpublished from Study I) 
 
At baseline, nine patients (14.1%) showed physical evidence, i.e. needle marks of intravenous 
drug misuse and seven of them reported abused mono-buprenorphine and two abused heroin. 
Forty-seven patients (73.4%) indicated that they were not abusing mono-buprenorphine or 
heroin and showed no signs of intravenous misuse or positive urine opioid tests. Information on 
intravenous misuse of mono-buprenorphine was not recorded for eight patients (12.5%) prior to 
switch, for 3 at week one (4.7%), one at week two (1.6%) and three (1.6%), 2 at week four 
(3.1%) and eleven during follow-up (18%). At weeks one, two and three, signs of intravenous 
abuse of mono-buprenorphine or buprenorphine-naloxone were seen in 11% (n = 7), 4.7% (n = 
3), and 9.4% (n = 6), respectively. Three patients who had records of intravenous misuse at 
baseline did not continue misusing during the four-week follow-up period, and three new 
patients with intravenous misuse were observed during this period. Over the four-week study 
period, there was no evidence of misuse of other opioids. During the follow-up period, 16.4% 
(n = 10) showed signs of intravenous buprenorphine abuse, one patient (1.6%) informed the 
investigator havering used heroin.  
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(Table 6). Of the buprenorphine intravenous abuse, buprenorphine-naloxone was misused by 
8.2% (n = 5), once each by four patients and twice by one patient.  
 
 
a: Patient told the investigator having used heroin. 
 
Table 6: Signs of Intravenous Misuse by Treatment Centre (unpublished from Study I) 
 
 
Patient treatment compliance information was collected for the four-week study period. 
Compliance was related to regular visit attendance, appropriate medication intake, and history 
or signs of misuse. Overall, 60.0% of patients were compliant with buprenorphine-naloxone 
treatment throughout the four-week study period. Overall compliance decreased slightly during 
the first week, but stayed at the same level for the rest of the four-week study period. The 
highest rate of compliance occurred at Centre Raahe where all patients were compliant with 
buprenorphine-naloxone treatment throughout the four-week study period. Centre HDL had a 
relatively high rate of compliance for the first three days after the switch, but by the end of the 
first week, only two of the nine patients (22.2%) were compliant with the buprenorphine-
naloxone treatment and it stayed at this level through the rest of the four-week study period 
 
Whether treating patients with buprenorphine-naloxone affects the frequency of patient misuse 
of buprenorphine could not be determined from this study. During the 4-week study period 
other drugs were misused including 10 patients cannabis (15.6%), 2 patients benzodiazepines 
(3.1%) and 1 patient amphetamines (1.6%). During the follow-up period other drugs were 
misused including 4 patiens amphetamines (6.6%) and1 patient each benzodiazepines (1.6%) 
and zolpidem 1.6%). 
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lack of compliance and during the four-month follow-up period, six patients discontinued due 
to a lack of compliance, 3 at HDL, 2 at Tre K-klinikka and 1 at HUS.  
 
 
 
Figure 7: Treatment compliance at each study centre (unpublished data based on data from Study I) 
 
 
Twenty-four patients (37.5%) were satisfied with the switch from mono-buprenorphine to 
buprenorphine-naloxone every time the question was asked during the four-week study period 
and 26 patients (40.6%) were dissatisfied every time they were asked. The 14 other patients 
(21.9%) were satisfied at some point during the four-week study period and nine of these 
patients were satisfied at the end of the four-week study period. Twenty-six of the 27 patients 
(96.3%) who were still being treated with buprenorphine-naloxone at the end of follow-up were 
satisfied (Figure 8). During the four-month follow-up period, four patients discontinued 
buprenorphine-naloxone treatment, 2 from HDL and Espoon A-klinkka, because of 
dissatisfaction with it.  
 
From some of the comments recorded at clinical visits, dissatisfaction and non-compliance was 
a reaction to being forced to switch from mono-buprenorphine to buprenorphine-naloxone. 
 
(Figure 7). During the four-week study period, two patients from HDL discontinued due to a 
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Figure 8: Patient satisfaction with switch at each study centre (unpublished data based on data from Study I) 
 
 
During the four-week observation period, 32 of the 64 patients (50.0%) reported adverse 
events. The adverse events were mostly mild withdrawal symptoms associated with the switch 
from mono-buprenorphine to buprenorphine-naloxone. During the follow-up period, 19 of the 
61 patients (31.1%) treated reported adverse events. Overall, 35 patients (54.7%) treated with 
buprenorphine-naloxone alone or in combination with mono-buprenorphine reported adverse 
events through the whole study period. There were three patients who experienced adverse 
events that were considered to be severe by the investigator during the four-week study period. 
During the follow-up period, only one  adverse event wasconsidered to be severe. One patient 
discontinued treatment with buprenorphine-naloxone during the four-week study period due to 
adverse events at Espoon A-klinikka and six patients discontinued due to adverse events during 
the follow-up period, 1 at Tampere K-klinikka and Espoon A-klinikka, and 4 at HUS/Opri. 
There were no deaths or serious adverse events in this group of patients. 
 
5.2.3 Bioavailability of mono-buprenorphine, crushing mono-buprenorphine tablets 
 
The aim of Study II was to investigate whether crushing the buprenorphine tablets before 
administering it to patients in order to minimize the risk of medication diversion would affect 
the efficacy of medication. Measuring mono-buprenorphine serum levels, the peak 
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buprenorphine T max  serum level was observed approximately 1 hour after administration of 
the crushed tablets, and the mean was 1.44 h ± 0.6 (SD); the mean for whole tablets was 1.68 h 
± 1.4 (SD). The C max (ng/ml) was 9.727 ng/ml ± 3.4 (mean ± SD) for crushed tablets and 
9.591 ± 3.8 for whole tablets. These differences were not significant (Figure 9). The differences 
were even smaller with norbuprenorphine with serum levels almost identical in both study 
groups on both study days (Figure 10). 
 
 
 
 
Figure 9: Mean buprenorphine serum concentrations, grouped by crushing, all subjects (published 
in Study II)  
 
 
 
 
 
Figure 10: Mean norbuprenorphine serum concentrations, grouped by crushing, all subjects 
(unpublished from Study II)  
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The study subjects were interviewed before they received study medication and at 5h and 24h 
after administration to estimate the opioid withdrawal by using SOWS and craving by using 
VAS. There was no significant difference between the withdrawal average scores when the 
study subjects received whole or crushed mono-buprenorphine tablets, although the scores 
varied from 0 to 42 points. There was also no difference in the opioid craving scores, as 
measured by VAS, between the groups, visits or mode of drug administration (crushed and 
whole tablets). There were no significant differences between average tablet dissolution time of 
whole and crushed tablets (Table 7). 
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Table 7: Withdrawal and VAS scores, and dissolution time for whole and crushed tablets 
(published in Study II) 
 
 
In total, nine different study subjects reported adverse events during the study. In the whole 
tablet group, four patients reported adverse events (fatigue and dysphoria). In the crushed tablet 
group, eight participants reported six events (pollacisuria, fatigue, headache, strange feeling, 
craving and pain). Three subjects reported adverse events on occasions, one subject only when 
administered the whole tablet and five subjects only when administered the crushed tablet. 
There were more adverse events reported in the crushed tablet group. No severe adverse events 
were reported.  
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5.3 The effect of a new drug screening method on treatment adherence, patient 
compliance and time spent on screening 
 
In Study III, 168 samples were collected; 69% for the new method (NM) test group (n = 116), 
and 31% in the traditional sampling (TS) test group (n = 52). In the NM group, the total return 
rate was 98.3% (n = 114). When the samples were taken home, which was done in 87% (n = 
101) of the NM cases, the return rate was 97% (n = 98) (Figure 11). For the NM, drug analyses 
were done at the laboratory and all positive results were confirmed by the HPLC method. 
Benzodiazepines was the most and opioids were the rarest drugs found; buprenorphine was not 
included in the drug analyses, because it was the OMT medication many patients  (Figure 12). 
 
 
 
 
 
 
Figure 11: The return rate (n) of urine samples in the new marker group. P=0.9474 (published in 
Study III). 
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Figure 12: Number of positive drug analyses in the new marker group, one urine sample could 
be positive for several substances (unpublished data from Study III) 
 
 
Of the 57 patients participating in the study, 53 returned the questionnaire (93%). Subjects were 
also asked what they had experienced with the method to which they had been assigned during 
randomization. In the NM group, 94% (n = 31) answered the question of whether “taking the 
marker was an unpleasant experience”, and 83.9% (n = 26) stated that it was not unpleasant 
(Chi2=1.44935 df=1 P=0.2286). On a 1–6 point scale the question “How unpleasant is the 
waiting time after taking the marker before giving the urine sample?” was answered by 96.7% 
(n = 32) of the NM group. The mean score of their answers was 1.9. In the TS group, 84% 
answered the question “How unpleasant is it to provide a urine sample under supervision?”, 
which was rated on a 1–6 point scale and the mean score was 2.9. 
 
When asked which method the subjects would prefer, 96.7% (n = 32) of the NM test group 
answered the question; in this group, 71.9% (n = 23) preferred marker testing, 18.7% (n = 6) 
supervised testing, and 9.4% (n = 3) had no preference. In the TS test group, 80% (n = 20) 
answered the question; 60% (n = 12) preferred the marker system and 40% (n = 8) preferred 
supervised testing (Chi2=3.63805 df=2 P=0.1621).  
""&
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On a 1–6 point scale the personnel rated the unpleasantness of preparing and giving the NM 
test as 1.2 (mean). The unpleasantness of supervising patients (TS group) was rated at 3.4 
(Chi2=2.99761 df=1 P=0.0833). All employees preferred to administer the NM test. While 
answering the questionnaire, some staff members commented verbally (unpublished) that urine 
sample collection was unpleasant only with the traditional, supervised method due to the low 
level of patient cooperation or the long urination time. 
 
The employees were also asked to estimate the total average working time (in minutes) that 
they needed for one urine sample and also to estimate how much working time the NM test 
saves (Figure 13). For TS urine samples, 40% took 5-10 minutes, 50% took 10-20 minutes, and 
10% required over 20 minutes. When using the NM test, 30% needed less than 5 minutes and 
70% took between 5 and 10 minutes. One staff member was unable to estimate the time saved 
due to limited experience with the method. 
 
 
 
 
 
Figure 13: Employee estimation of how much working time was saved by using the new 
marker method (published in Study III) 
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Eight employees also commented on the effects of urine testing on the staff–patient 
relationship. Most stated that TS testing has a negative impact on openness in therapeutic 
treatment, especially if the supervisor is also the patient’s therapist. Many employees expressed 
the opinion that supervising may lead to manipulation attempts, due to the mistrust felt by 
patients. Interestingly, there were several comments that using the NM test also includes a 
therapeutic element, as the patient is given responsibility for his/her own treatment. A majority 
of comments referred to the working time saved and ease of applying the NM test. 
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6. Discussion 
6.1 Main findings 
 
The combination buprenorphine-naloxone was introduced to help eliminate diversion and 
intravenous use of buprenorphine. The combination is supposed to have a lower potential for 
intravenous abuse than mono-buprenorphine alone. In Study IV the prevalence of responders 
for lifetime buprenorphine-naloxone abuse did rise from 68%, to 80.5%, and the number of 
respondents abusing buprenorphine-naloxone more frequently did increase clearly, indicating 
that the abuse potential was perhaps not so low as expected when the product was taken into 
use. One reason for this could be the fact that mono-buprenorphine was already the most 
abused opioid in Finland (Uosukainen, Kauhanen et al. 2013), which is different from many 
other countries, lowering the threshold to try abuse buprenorphine- naloxone and the naloxone 
effect due to the pre-existing mono-buprenorphine receptor binding. One other reason could be 
that buprenorphine-naloxone is the mainly used medication formulation in OMT  in Finland 
and it is known that the more an intoxicating medication is used in treatment the higher is the 
overall misuse. Even in this kind of environment, daily use of buprenorphine- naloxone 
(14.7%) was still clearly lower than with mono-buprenorphine (74.3%). One reason could be 
the finding that 80% reported that they had a “bad” experience with the combination product, 
while less than 20% reported it “similar” to experiences with intravenous mono-buprenorphine, 
which was published from the same data in another article (Alho, Sinclair et al. 2007) and also 
in other studies (Hakansson, Medvedeo et al. 2007; Bazazi, Yokell et al. 2011). Also only a 
fifth had never tried it in 2010 compared to one third in 2005, when the buprenorphine-
naloxone street price was over 50% lower than that of mono-buprenorphine. During the period 
studied, the street price of both mono-buprenorphine and buprenorphine-naloxone rose, but the 
price difference remained and in 2010 buprenorphine-naloxone was still over 40% cheaper than 
mono-buprenorphine. However due to the street value, which parallels the abuse potency, and 
the fact that under 15% of respondents used buprenorphine-naloxone frequently, it could be 
concluded that the lower potential of regular abuse did not significantly decrease even after 
being available on the street market for years and being abused more frequently. This is also 
seen in opioid abusers seeking treatment of whom 92% abused mono-buprenorphine and 8% 
buprenorphine-naloxone in 2010 (Väänänen 2011). In 2011 the amount of buprenorphine-
naloxone abuser seeking treatment had fallen to 5% (Väänänen 2012). 
  
64 
 
 
Buprenorphine has been the most abused opioid in Finland since the beginning of this century 
(Alho, Sinclair et al. 2007; Uosukainen, Kauhanen et al. 2013). This study gave new 
information about the misuse pattern of opioid abusers. On average, abusers had abused with 
other opioids for 2.5–3 years before switching to buprenorphine. According to the data, these 
were mainly prescription opioids. Data produced by KELA, the Social Insurance Institution of 
Finland, on the “number of recipients and prescription data” shows that the number of patients 
receiving opioids has more than doubled between 2008 and 2011, from 166 271 to 409 185, the 
biggest group being the 312 955 patients receiving codeine (KELA 2012). Considering this in 
combination with the data from this study it seems likely that there is a connection between 
these trends, because prescription opioids are much easier to obtain and cheaper than 
buprenorphine, and thus likely the main abused opioids in the first years of misuse. Taking into 
account that in 2008 only 1.6% and in 2010 1.4% reported using oxycodone intravenously, 
which are low percentages compared to international data, which found for example that 4.8% 
abused oxycodone intravenously (SAMSHA 2011) in the USA in 2010 and this appears to be a 
rising problem (Aquina, Marques-Baptista et al. 2009; Fischer B. 2010; Butler, Black et al. 
2011; Roxburgh 2011; Fischer B. 2012; SAMHSA 2012). It is surprising that there has been no 
research on this issue in Finland especially when considering that at least occasionally of 
patients’ entering treatment 4% abused tramadol, 4% oxycodone, 3 % codeine preparations and 
1 %fentanyl (Väänänen 2012). This is a clear deficiency, and a discussion regarding the clinical 
practices of opioid prescription should certainly be initiated quickly. A change was also seen in 
the way of abusing buprenorphine- naloxone especially in the rise of intranasal abuse, which is 
in line with EU trends where a decline in intravenous abuse and a rise in other ways of abuse is 
seen (EMCDDA 2012a), which also has pharmacodynamic and pharmacokinetic backgrounds 
(Middleton, Nuzzo et al. 2011). 
 
According to the results of the study, OMT was discontinued more often after the switch to 
buprenorphine-naloxone than in other international studies (Montesano, Zaccone et al. 2010) or 
OMT dropouts observed in other Finnish studies (Pirkola, Heikman et al. 2007; Vorma 2009): 
treatment was terminated by 11.7 % and to methadone were transferred 21.7%. The latter is 
very high considering the rather low rate of concomitant drug abuse, which is the main reason 
for this transfer, recorded by the study sites. There is also quiet a big difference between the 
study sites as to patient satisfaction. The greatest patient satisfaction and fewest numbers of 
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adverse events was recorded at Treatment Centre RAAHE. Even though each patient at this 
centre only visited once a week, patients lived at the treatment centre and were provided with 
lots of counselling before and during the switch from mono-buprenorphine to buprenorphine-
naloxone. The counselling provided the patients with information about buprenorphine-
naloxone treatment and gave them the possibility to discuss their concerns. The positive results 
from this centre are most likely a result of the counselling and information provided by the 
centre personnel. Comments from the treatment centre physicians indicate that patients who 
have been switched more recently have had fewer adverse events and the switch has been more 
successful. The physicians believe that this newer group of patients was better informed about 
buprenorphine-naloxone treatment. Insufficient medication effect was reported by 2 patients 
contrary to a remarkable proportion (57.7%) of patients who wanted to lower their dose. The 
study indicates that forcing patients into treatment regimens, i.e. medication switch, did 
negatively affect compliance. It was seen with the switch from mono-buprenorphine to 
buprenorphine–naloxone, when treatment discontinuation increased considerably. This 
emphasizes the importance of cooperation with the patients when making decisions regarding 
treatment management (Mikkonen A. 2008).  
 
Lowering the supervision of medication does result in increasing adherence without 
compromising treatment outcomes, for example, in the form of opioid abuse and overdoses 
(Bell, Shanahan et al. 2007). However, at the same time it has been shown that less supervision 
could increase diversion (Monte, Mandell et al. 2009). On the other hand supervision binds 
resources, which may lead to limited access, which could itself increase mortality rates 
(Nilsson I. 2012). In this respect the transfer to buprenorphine-naloxone may also serve as part 
of an overall strategy to curb misuse of buprenorphine. This is an important observation 
because the abuse of mono-buprenorphine is a rising problem in many countries (Hakansson, 
Medvedeo et al. 2007; Wish, Artigiani et al. 2012). Based on the fact that participants were 
only asked in 2010 where they had bought their buprenorphine-naloxone (without specifying 
the origin), no solid conclusions about buprenorphine-naloxone diversion from treatment units 
could be made, but it seems clear that mono-buprenorphine is still the first preferred opioid of 
abuse of these two formulations. This underlines the conclusion that the use of the 
buprenorphine-naloxone combination formulation could be a possibility for reducing controlled 
dispensing without greatly increasing the risk of diversion (Stimmel 2007; Johanson, Arfken et 
al. 2012). This has led to the consideration in many countries, such as France, Spain and 
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Portugal, of a wider use of buprenorphine–naloxone (Courty 2012; Patricio 2012; Teran 2012; 
Touzeau 2012). However, recent publications suggest that abuse of the buprenorphine–
naloxone combination would be a growing problem (Bazazi, Yokell et al. 2011; Johanson, 
Arfken et al. 2012). It has been shown that patients in combination medication treatment can 
inject without any adverse symptoms (Bruce, Govindasamy et al. 2009; Mammen and Bell 
2009). Whether treating patients with buprenorphine-naloxone affects the frequency of patient 
misuse of buprenorphine could not be determined from this study, though the results could still 
lead to the conclusion that the full potential of the buprenorphine-naloxone formulation is 
probably achieved in environments where mostly opioids other than mono-buprenorphine are 
abused. Pharmacological research indicates (Strain, Walsh et al. 2002; Correia, Walsh et al. 
2006) that the naloxone compound diminishes the abuse viability, which can lead to the 
assumption that a clinical setting in which the medication is used could have a more important 
impact regarding diversion and misuse (Mammen and Bell 2009). This was also indicated in 
this study when looking at patient compliance, satisfaction, treatment termination at different 
study site after switching medication to buprenorphine-naloxone. There is very little clinical 
research on this specific issue, however, offering treatment that is more than just medication 
alone should be emphasized (Amato, Minozzi et al. 2004b; Amato, Minozzi et al. 2004c; 
Fiellin, Pantalon et al. 2006; Amato, Minozzi et al. 2008b). In all treatment settings the patients 
should have the possibility to modify their addictive behaviour, which includes intravenous 
misuse (Vidal-Trecan, Varescon et al. 2003; AIHW 2010). 
 
Due to the chronic nature of opioid dependence, treatment is long-term, even lifelong, and if 
the resources of the OMT are not increased, the treatment capacity will gradually fill up and 
less and less new patients can be included. This issue has become even more important because 
financial resources remain at the same level which hinders access to treatment (Tanhua H., 
Virtanen A. et al. 2011). The aim of this thesis was to explore what factors could improve 
patient compliance and adherence to the treatment, and thus OMT outcomes, without leading to 
an intolerable increase of unwanted harm related to treatment like medication diversion. One 
way of achieving this is the crushing of buprenorphine tablets, which according to the data has 
no effect on blood concentration, withdrawal symptoms or craving, and makes it possible to use 
the medication in patient groups with a high risk of diversion. This is clinically relevant for 
patients at high risk for diversion or attempted buprenorphine smuggling from supervised 
medication suspension. Crushing the medication is an good alternative to treatment termination 
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or to being switched onto methadone, which in many countries, including Finland, is often 
conducted for high risk patients. Methadone is dispensed in a liquid form that makes 
controlling and observation easier, faster and the smuggling of medication from the clinic 
harder (Winstock, Lea et al. 2008). Crushed mono-buprenorphine has been in wider clinical use 
in Ireland (NSHHB 2006) were clinicians where advised to review their patient to determine 
that mono-buprenorphine is being swallowed rather than dissolved, or if it is being diverted. 
This guidance was given in 2006 regardless of the fact that at that point no studies had been 
carried out on the effect on the bioavailability of mono-buprenorphine after crushing the 
tablets. It was hypothesized that crushing increases the surface area of the drug which would in 
turn increase the dissolution and absorption of the drug. It was also suspected also that crushing 
would increase saliva production, which in turn would enhance the possibility of swallowing 
unabsorbed drug. As shown in this study, the absorption was not altered by crushing but the 
possibility of increased swallowing decreasing the medications effect could not be verified nor 
rebutted. It seems that the rationale behind this guidance was patient control rather than 
enhancing treatment availability. What should be considered is that this patient group are often 
at high risk of concomitant drug consumption in which case the safety profile of buprenorphine 
may be an advantage. 
 
Patient compliance is also often affected by supervised urine testing, because it is regarded 
unpleasant both by patients and staff. For the treatment unit  personnel, supervision also sets 
challenges: personnel shortage due to same gender controls, organizational delays and extra 
work due to significant expenditure of time, lack of daily routine planning reliability, and last 
but not least, the fact that control of manipulation is not the job of  trained medical staff. Their 
competence should be used for treatment, e.g. counselling, which is in the end more important 
for patient rehabilitation and treatment outcomes, than urine drug screening. The use of a new 
method for drug screening was well accepted by patients, significantly saved on working time 
and did not compromise treatment safety in terms of undetected concomitant drug abuse. This 
was in line with the small amount of published studies dealing with this method (Schneider, 
Ruhl et al. 2008). By using the new method the trained staff could focus on consultation rather 
than supervision, enhancing patient treatment and increasing the number of treated patients. 
There are new studies from Finland with other technical innovations, such as electronic 
compliance monitoring (Tacke, Uosukainen et al. 2009), showing that significant time and cost 
savings can be achieved with those techniques. This is important, because the number of opioid 
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abusers seeking treatment has, according to this study, almost doubled from 2006 to 2010 and 
the mean opioid abuse time has also risen implicating that there still is an unmet need for 
treatment at least in the metropolitan area.  
 
 
6.2 Methodological considerations and limitations  
 
Study I was a retrospective evaluation and, given the nature of the study, there was no control 
group. The appropriate clinical patient data were used to assess any safety, adverse events and 
compliance changes associated with a switch from mono-buprenorphine to the buprenorphine–
naloxone combination product. Data were received from the treatment centres on case report 
forms and descriptive statistics were used for summarising. However, the data collected was 
inspected by the research group, while the variables in this study have been used in other 
studies on opioid dependence, and should therefore be appropriate. Study I is limited by its 
retrospective nature and the differences in clinical practice between the study sites. The 
treatment procedures did differ in the centres especially in respect of the policy on take-home 
medication, urine testing and also determination of treatment due to drug abuse. Also 
counselling provided to the patients with information about buprenorphine-naloxone treatment 
did differ at the study sites. Probably there was also a difference how physicians did record, e.g. 
drug abuse, adverse effects and carry out needle mark inspections. What also has to be 
considered is the attitude of the physicians themselves towards the buprenorphine-naloxone 
product. If the physician had any doubt concerning the safety or efficacy of the product it 
would be exceptional if this would have had no effect on the patients. This could explain the 
high (15%) switch back to mono-buprenorphine. However, the main aim was to determine the 
doses of buprenorphine-naloxone associated with acceptable adverse events during the switch 
of medication from mono-buprenorphine, and this should not compromise the value of the data. 
 
In Study II, the SOWS and VAS indicators were used to estimate opioid withdrawal symptoms 
and craving. Although they are both validated in Finland and clinically widely in use, they are 
subjective measurements and they cannot be used to compare results with the other study 
subjects. In order to avoid this problem a crossover design was used. Data collection for Study 
II was started in May 2004, which was half a year after the majority of maintenance patients 
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were switched to buprenorphine-naloxone. The study size was calculated to be sufficient for 
reliable data analyses. The main limitation is related to the study design, where patients were 
stabilized on 24 mg of mono-buprenorphine and then had whole or crushed medication in 
seven–day intervals. The stabilization time (two weeks) for these patients was, according to 
prior pharmacokinetic studies, sufficient to prevent interference with the gathered data. When 
plasma levels are measured in a steady state dosing situation, buprenorphine in the plasma 
comes partly from the dosing period being examined and partly from previous doses. This is 
shown by the plasma level measured at time zero or pre-dose; the buprenorphine in the plasma 
at this time is clearly from the previous dose(s). At steady state, which the study could claim 
after seven days of regular, fixed dosing, the area under the plasma curve (AUC) between zero 
and 24 hours (the interdose period) is equal to the AUC from zero to infinity following a single 
dose and gives an acceptable means of comparison of the two treatments. Therefore, when 
whole tablets have been taken for seven days and then as the whole tablet test dose, the plasma 
levels between zero and 24 hours are fully representative of whole tablets at steady state. 
However, when whole tablets have been taken for seven days but the test dose is crushed 
tablets, then the plasma levels between zero and 24 hours are represented by a mixture of the 
contribution of the whole tablets and the crushed tablet test dose. So the study cannot claim that 
the plasma levels are representative of crushed tablets at steady state. Although the study does 
not meet generic bioequivalence standards according to the FDA, this study still provides 
valuable information for clinical practice. 
 
Study III included a questionnaire that was created for this study only and has not been 
validated. The questionnaire included background information, two questions measuring 
patient satisfaction on a six-point Likert scale, and the patient’s preferred testing system. The 
use of a unique questionnaire makes comparison to other studies difficult, but on the other hand 
a 1–6 scale is widely used for assessment research. Study III had several limitations. First the 
study sample was collected from three different patient groups (maintenance treatment, 
detoxification and outpatient unit), and may thus have some selection bias. Also the number of 
reported attempts at manipulation could be biased, as patients in different phases or treatments 
have a different motivation to manipulate their urine depending on the advantages they might 
obtain when providing a negative drug result. The focus of this study, however, was on 
analysing the risk of manipulation when using the new marker method and patient compliance 
and staff satisfaction.  
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Study IV was based on a questionnaire. One of the major challenges in the data analysis was 
grouping the declared data on the drug of abuse into the correct categories, given that a lot of 
street names for the drugs were used. For each uncertain drug name, the participating study site 
was asked to provide as precise an estimate as to which group it should be categorised into. The 
categories were kept the same over the full period of the study so as to maintain comparability. 
Study IV has two main limitations: firstly the response rate varied greatly between the study 
years and it was not possible to calculate for every year the exact return rate due to the 
anonymity of the service. Secondly the questionnaires used differed slightly annually and the 
questions were partly phrased differently, which may lead to some bias. However, the content 
of the questions of the main variables were similar. On the other hand, it seems that grouping 
between opioid and non-opioid users was successfully conducted over the years, because the 
response rates were similar to the portion of opioid abusers of overall intravenous users in 
Finland, and regardless of the different phrasings, the meaning of the questions were the same 
from one year to another. 
 
All studies, except IV, have too small sample sizes to infer strong conclusions.  
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7. Conclusions and future implications 
 
Reports and studies from countries with a long history of OMT have shown that when 
treatment access is expanded, the harms related to treatment tend to increase (Ritter and Di 
Natale 2005; Monte, Mandell et al. 2009; AIHW 2010). Several different approaches can be 
taken to diminish the misuse of treatment medication, diversion and overdoses in particular. At 
the same time the balance between higher costs of supervision and its impact on access to 
treatment needs to be considered. Increased supervision binds resources, with less treatment 
available overall, resulting in higher mortality, infection and crime rates. On the other hand a 
lack of adequate supervision leads to more medication misuse and diversion. However, 
management of the OMT is not so one-sided, as the use of safer preparations with lower abuse 
potential have opened new possibilities to carry out medication dosing in a more flexible way 
(Amass, Kamien et al. 2000; Perez de los Cobos, Martin et al. 2000; Petry, Bickel et al. 2000; 
Amass, Kamien et al. 2001; Bell, Shanahan et al. 2007; Amass, Pukeleviciene et al. 2012). This 
allows for a less supervised administration of the medication (Bell, Shanahan et al. 2007), 
without negatively effecting two of the primary outcomes; opioid abuse and retention. It is also 
important to make OMT more and more available in primary care, where it is easily accessible 
for patients (Amass, Ling et al. 2004; Wittchen, Apelt et al. 2008; Lee, Grossman et al. 2009), 
is more cost-effective (Jones, Moore et al. 2009; Schackman, Leff et al. 2012), and also allows 
new patients to enter into treatment (Sullivan, Chawarski et al. 2005) with good outcomes 
(Fudala, Bridge et al. 2003; Fiellin, Moore et al. 2008). Good treatment availability is also an 
important factor in declining the number of new drug, especially opioid, abusers, which has 
been detected at EU level after rises in treatment access possibilities (EMCDDA 2012a). This 
should also be more emphasized in Finland because there is still a burden for treatment access, 
and many opioid abusers are not able to get OMT even if they wanted to. More research is 
needed to clarify the reasons why patients are unable to enter OMT. 
 
Repeated research has demonstrated that it is important  to invest in the education of treatment 
personnel (Lofwall, Wunsch et al. 2011). Untrained personnel lack medical knowledge and 
knowledge of prescription practices (Leonardi, Hanna et al. 2008; Barry, Irwin et al. 2009; 
Larance, Degenhardt et al. 2011c; Larance, Ambekar et al. 2011d, Johanson, Arfken et al. 
2012) or are using insufficient medication regimens (Roux, Villes et al. 2008a; Roux, Villes et 
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al. 2008b; Lofwall, Wunsch et al. 2011), which all may negatively effect treatment outcomes 
and also higher the risk of medication diversion. 
 
An important role in enhancing treatment efficacy is the possibility to use pharmacist 
dispensing, which has been possible in Finland for the buprenorphine–naloxone combination 
only since 2009 for patients treated with buprenorphine-naloxone. Considering international 
practices, clearly the proportion of patients receiving treatment in this way could clearly be 
higher. In the main, pharmacists are willing deal with supervised medication suspension 
(Raisch, Fudala et al. 2005; Lofwall, Wunsch et al. 2010) but caution has to be taken to ensure 
adequate education aimed at preventing diversion (Winstock, Lea et al. 2008), as well as 
considering financial issues, given that pharmacies are private enterprises (Winstock, Lea et al. 
2007). 
 
The combining of naloxone with buprenorphine has had positive outcomes on restricting 
diversion and misuse in Finland to some extent compared to mono-buprenorphine. In other 
opioid abuse surroundings the effect is probably more evident, also providing new possibilities 
for flexible medication dispensing. Patients’ attitudes towards combining with naloxone for 
safety reasons have become more accepting (Daulouede, Caer et al. 2010; Shearer, Mammen et 
al. 2010). Moreover, attempts to develop a methadone–naloxone combination product (Nutt 
and Jasinski 1974; Bell, Shearer et al. 2009) would also be a big step towards safer treatment. 
 
Treatment has clearly been shown to be cost-effective for mono-buprenorphine, 
buprenorphine–naloxone and methadone (Doran, Shanahan et al. 2003; Doran 2005; Martinez-
Raga, Gonzalez Saiz et al. 2010; Schackman, Leff et al. 2012) when compared to detoxification 
or no treatment, especially when using flexible medication dispensing (Baser, Chalk et al. 
2011; Weiss, Potter et al. 2011). Even though the costs of OMT have lately been the key issue 
in Finnish discussions, leading to suggestions for treatment models that involve only treatment 
with  medication, one needs to keep in mind that this trend involves great risks in terms of 
treatment outcomes. Addiction is a complicated disease and needs to be treated in a multi-
professional way, addressing flexibly the challenging psychological and social problems of 
patients. Counselling is needed in its various forms and its use on an individual basis is 
associated with better treatment outcomes (McLellan, Arndt et al. 1993; Galanter, Dermatis et 
al. 2004; Fiellin, Pantalon et al. 2006; Gorelick 2006).  
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Investing in individual treatment possibilities by, i.e. introducing new technical methods into 
clinical settings, goes hand in hand with the realisation that medication is not at the centre of 
treatment, but rather rehabilitation, which when successfully conducted increases confidence 
that the medication abuse is low. OMT has (Kirn 1988) and will remain controversial until 
better quality evidence on clinical management emerges. Improving treatment, safety concerns 
and health economics are complex questions, and there are no simple answers. Nevertheless, a 
lot can be achieved with good clinical management with no decrease in treatment quality. 
Regarding the severity of opioid addiction, treatment needs to be flexible and sufficiently long 
lasting. In most cases (cost-)effective treatment means tailored treatment schemes for 
individual patients. Most importantly, the background of OMT should be medical and ethical, 
not purely economic, otherwise, rising costs and diminishing treatment safety could lead to 
severe consequences – with a high price, paid for by patients and society alike. 
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